[P02BB01, trichlorfon, Metrifonate may increase the bradycardic activities of Nadolol.]
[S02DA03, antipyrine, Antipyrine may decrease the antihypertensive activities of Nadolol.]
[B01AD01, streptokinase, The risk or severity of adverse effects can be increased when Streptokinase is combined with Nadolol.]
[J01GA01, streptomycin, Nadolol may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[L04AA27, fingolimod, Nadolol may increase the bradycardic activities of Fingolimod.]
[M03AB01, succinylcholine, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Nadolol.]
[A02BX02, sucralfate, Sucralfate may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[J01CG01, sulbactam, Nadolol may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01EC02, sulfadiazine, The therapeutic efficacy of Sulfadiazine can be increased when used in combination with Nadolol.]
[J01EC01, sulfamethoxazole, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Nadolol.]
[S01AB02, sulfisoxazole, The therapeutic efficacy of Sulfisoxazole can be increased when used in combination with Nadolol.]
[M01AB02, sulindac, Sulindac may decrease the antihypertensive activities of Nadolol.]
[N05AL01, sulpiride, Sulpiride may increase the bradycardic activities of Nadolol.]
[A10BB04, glibornuride, The therapeutic efficacy of Glibornuride can be increased when used in combination with Nadolol.]
[A10BC01, glymidine, The therapeutic efficacy of Glymidine can be increased when used in combination with Nadolol.]
[M01AX04, apazone, Azapropazone may decrease the antihypertensive activities of Nadolol.]
[N06DA01, tacrine, Tacrine may increase the bradycardic activities of Nadolol.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Nadolol.]
[N05CD07, temazepam, Temazepam may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[R03CC03, terbutaline, Nadolol may decrease the bronchodilatory activities of Terbutaline.]
[B01AE07, dabigatran etexilate, Nadolol may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.]
[G03BA03, testosterone, Testosterone may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[N07XX06, tetrabenazine, The metabolism of Tetrabenazine can be decreased when combined with Nadolol.]
[S03AA02, tetracycline, Tetracycline may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[J01DI02, ceftaroline fosamil, Ceftaroline fosamil may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[N05AE05, lurasidone, Lurasidone may decrease the antihypertensive activities of Nadolol.]
[A04AD10, dronabinol, The metabolism of Nadolol can be decreased when combined with Dronabinol.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Nadolol.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Thalidomide is combined with Nadolol.]
[R03DA07, theobromine, Theobromine may increase the excretion rate of Nadolol which could result in a lower serum level and potentially a reduction in efficacy.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Nadolol.]
[P02CA02, thiabendazole, Thiabendazole may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[R06AD03, thiethylperazine, The serum concentration of Nadolol can be increased when it is combined with Thiethylperazine.]
[L01AC01, thiotepa, Thiotepa may increase the bradycardic activities of Nadolol.]
[N05CA19, thiopental, Thiopental may increase the hypotensive activities of Nadolol.]
[N05AB08, thioproperazine, The serum concentration of Nadolol can be increased when it is combined with Thioproperazine.]
[N05AC02, thioridazine, The metabolism of Nadolol can be decreased when combined with Thioridazine.]
[C01BB04, aprindine, Nadolol may increase the arrhythmogenic activities of Aprindine.]
[B02AB01, aprotinin, Aprotinin may increase the bradycardic activities of Nadolol.]
[G04BE06, moxisylyte, Moxisylyte may decrease the antihypertensive activities of Nadolol.]
[N05AL03, tiapride, Nadolol may decrease the excretion rate of Tiapride which could result in a higher serum level.]
[B01AC05, ticlopidine, The metabolism of Nadolol can be decreased when combined with Ticlopidine.]
[S01ED01, timolol, The risk or severity of adverse effects can be increased when Timolol is combined with Nadolol.]
[P01AB02, tinidazole, Tinidazole may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[S01AA12, tobramycin, Nadolol may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, The therapeutic efficacy of Tolazamide can be increased when used in combination with Nadolol.]
[M02AX02, tolazoline, Nadolol may increase the orthostatic hypotensive activities of Tolazoline.]
[V04CA01, tolbutamide, The therapeutic efficacy of Tolbutamide can be increased when used in combination with Nadolol.]
[M02AA21, tolmetin, Tolmetin may decrease the antihypertensive activities of Nadolol.]
[N02AX02, tramadol, Tramadol may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[N06AF04, tranylcypromine, The metabolism of Nadolol can be decreased when combined with Tranylcypromine.]
[N06AX05, trazodone, The serum concentration of Nadolol can be increased when it is combined with Trazodone.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Tretinoin is combined with Nadolol.]
[C03DB02, triamterene, Triamterene may increase the excretion rate of Nadolol which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD05, triazolam, Triazolam may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[C03AA06, trichlormethiazide, The therapeutic efficacy of Nadolol can be increased when used in combination with Trichlormethiazide.]
[S01EB04, demecarium, Demecarium may increase the bradycardic activities of Nadolol.]
[A16AX12, trientine, Nadolol may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.]
[N05AB06, trifluoperazine, The serum concentration of Nadolol can be increased when it is combined with Trifluoperazine.]
[S01AD02, trifluridine, Trifluridine may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[N05AA05, triflupromazine, The serum concentration of Nadolol can be increased when it is combined with Triflupromazine.]
[A03AA05, trimebutine, Nadolol may increase the arrhythmogenic activities of Trimebutine.]
[S01ED04, metipranolol, Nadolol may increase the arrhythmogenic activities of Metipranolol.]
[R06AD01, trimeprazine, The serum concentration of Nadolol can be increased when it is combined with Alimemazine.]
[N03AC02, trimethadione, Trimethadione may increase the arrhythmogenic activities of Nadolol.]
[C02BA01, trimethaphan, Trimethaphan may increase the hypotensive activities of Nadolol.]
[J01EA01, trimethoprim, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Nadolol.]
[N06AA06, trimipramine, The metabolism of Trimipramine can be decreased when combined with Nadolol.]
[R06AC04, tripelennamine, The metabolism of Nadolol can be decreased when combined with Tripelennamine.]
[N06AX24, vilazodone, The metabolism of Nadolol can be decreased when combined with Vilazodone.]
[C09CA09, azilsartan medoxomil, Nadolol may increase the hypotensive activities of Azilsartan medoxomil.]
[M03AA02, tubocurarine, Tubocurarine may increase the bradycardic activities of Nadolol.]
[R03DX07, roflumilast, Nadolol may decrease the excretion rate of Roflumilast which could result in a higher serum level.]
[L01FX04, ipilimumab, Nadolol may decrease the excretion rate of Ipilimumab which could result in a higher serum level.]
[S01AA05, tyrothricin, Tyrothricin may increase the bradycardic activities of Nadolol.]
[R02AA14, oxyquinoline, Nadolol may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[L02BX03, abiraterone, The metabolism of Nadolol can be decreased when combined with Abiraterone.]
[A10BH05, linagliptin, The therapeutic efficacy of Linagliptin can be increased when used in combination with Nadolol.]
[J05AG05, rilpivirine, The metabolism of Nadolol can be decreased when combined with Rilpivirine.]
[S01AA28, vancomycin, Nadolol may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[N03AX21, ezogabine, Nadolol may decrease the excretion rate of Ezogabine which could result in a higher serum level.]
[B01AF01, rivaroxaban, Nadolol may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.]
[R03AC18, indacaterol, Nadolol may decrease the bronchodilatory activities of Indacaterol.]
[C08DA01, verapamil, The risk or severity of adverse effects can be increased when Verapamil is combined with Nadolol.]
[N06AX09, viloxazine, The metabolism of Nadolol can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Nadolol can be decreased when combined with Vinblastine.]
[C04AX07, vincamine, Nadolol may increase the hypotensive activities of Vincamine.]
[B03BA01, vitamin B12, Cyanocobalamin may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[B01AA03, warfarin, Nadolol may decrease the excretion rate of Warfarin which could result in a higher serum level.]
[S01AA13, fusidic acid, The metabolism of Nadolol can be decreased when combined with Fusidic acid.]
[N01AX15, xenon, Xenon may decrease the antihypertensive activities of Nadolol.]
[C03BA10, xipamide, Xipamide may increase the excretion rate of Nadolol which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AF05, zuclopenthixol, Nadolol may increase the orthostatic hypotensive activities of Zuclopenthixol.]
[L01EC01, vemurafenib, The metabolism of Nadolol can be decreased when combined with Vemurafenib.]
[M05BA03, pamidronic acid, Pamidronic acid may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[M05BA05, tiludronic acid, Tiludronic acid may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[B06AC02, icatibant, Nadolol may decrease the excretion rate of Icatibant which could result in a higher serum level.]
[L01ED01, crizotinib, Crizotinib may increase the bradycardic activities of Nadolol.]
[A02BC04, rabeprazole, Rabeprazole may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[N05AE04, ziprasidone, Ziprasidone may increase the antihypertensive activities of Nadolol.]
[G03AC10, drospirenone, Drospirenone may increase the excretion rate of Nadolol which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AC02, deferiprone, Nadolol may decrease the excretion rate of Deferiprone which could result in a higher serum level.]
[N02BA01, aspirin, Acetylsalicylic acid may decrease the antihypertensive activities of Nadolol.]
[L01EJ01, ruxolitinib, Ruxolitinib may increase the bradycardic activities of Nadolol.]
[G04BD07, tolterodine, Tolterodine may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[J01DH04, doripenem, Nadolol may decrease the excretion rate of Doripenem which could result in a higher serum level.]
[C07AB03, atenolol, Atenolol may increase the arrhythmogenic activities of Nadolol.]
[L01FA01, rituximab, Nadolol may increase the hypotensive activities of Rituximab.]
[S01FA01, atropine, Atropine may increase the arrhythmogenic activities of Nadolol.]
[M01CB03, auranofin, Auranofin may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[B03XA04, peginesatide, Nadolol may decrease the excretion rate of Peginesatide which could result in a higher serum level.]
[L01BC07, azacitidine, Azacitidine may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[L04AX01, azathioprine, Azathioprine may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[L01BC05, gemcitabine, Gemcitabine may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[J01DF01, aztreonam, Aztreonam may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[R02AB04, bacitracin, Bacitracin may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[G04BE10, avanafil, Nadolol may increase the hypotensive activities of Avanafil.]
[M03BX01, baclofen, The risk or severity of adverse effects can be increased when Baclofen is combined with Nadolol.]
[A08AA11, lorcaserin, The metabolism of Nadolol can be decreased when combined with Lorcaserin.]
[G04BD12, mirabegron, The serum concentration of Nadolol can be increased when it is combined with Mirabegron.]
[V03AX03, cobicistat, The metabolism of Nadolol can be decreased when combined with Cobicistat.]
[L02BB04, enzalutamide, Nadolol may decrease the excretion rate of Enzalutamide which could result in a higher serum level.]
[C01CA18, octopamine, The therapeutic efficacy of Octopamine can be decreased when used in combination with Nadolol.]
[L01EX05, regorafenib, Regorafenib may increase the bradycardic activities of Nadolol.]
[N05CA04, barbital, Barbital may increase the hypotensive activities of Nadolol.]
[C01AA01, acetyldigitoxin, Acetyldigitoxin may increase the arrhythmogenic activities of Nadolol.]
[D02BA02, octinoxate, Nadolol may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[S01GA07, brimonidine, Brimonidine may increase the antihypertensive activities of Nadolol.]
[N04BD02, rasagiline, Rasagiline may increase the hypotensive activities of Nadolol.]
[C08CA13, lercanidipine, Lercanidipine may increase the arrhythmogenic activities of Nadolol.]
[N06DA02, donepezil, Donepezil may increase the bradycardic activities of Nadolol.]
[L04AA29, tofacitinib, Nadolol may increase the bradycardic activities of Tofacitinib.]
[N02CC03, zolmitriptan, Zolmitriptan may decrease the antihypertensive activities of Nadolol.]
[G04BD10, darifenacin, The metabolism of Nadolol can be decreased when combined with Darifenacin.]
[V09IX04, fluorodeoxyglucose F18, Nadolol may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[N01AA01, ethyl ether, Diethyl ether may decrease the antihypertensive activities of Nadolol.]
[H01CB05, pasireotide, Nadolol may increase the bradycardic activities of Pasireotide.]
[G04BE03, sildenafil, Sildenafil may increase the antihypertensive activities of Nadolol.]
[V08CA11, gadofosveset, Nadolol may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Nadolol.]
[A16AX08, teduglutide, Nadolol may decrease the excretion rate of Teduglutide which could result in a higher serum level.]
[C04AX11, bencyclane, Nadolol may increase the arrhythmogenic activities of Bencyclane.]
[A10BH04, alogliptin, The therapeutic efficacy of Alogliptin can be increased when used in combination with Nadolol.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Nadolol can be decreased when combined with Glycerol phenylbutyrate.]
[L04AX06, pomalidomide, Nadolol may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[G03XC05, ospemifene, The metabolism of Nadolol can be decreased when combined with Ospemifene.]
[N02BA10, benorilate, Benorilate may decrease the antihypertensive activities of Nadolol.]
[A10BK02, canagliflozin, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Nadolol.]
[A06AX06, tegaserod, The metabolism of Nadolol can be decreased when combined with Tegaserod.]
[H03AA04, tiratricol, The therapeutic efficacy of Tiratricol can be decreased when used in combination with Nadolol.]
[A10AE05, insulin detemir, The therapeutic efficacy of Insulin detemir can be increased when used in combination with Nadolol.]
[R02AD01, benzocaine, The metabolism of Nadolol can be decreased when combined with Benzocaine.]
[A10BX05, pramlintide, The therapeutic efficacy of Pramlintide can be increased when used in combination with Nadolol.]
[L03AA12, ancestim, Nadolol may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, Celecoxib may decrease the antihypertensive activities of Nadolol.]
[N02CC02, naratriptan, Naratriptan may decrease the antihypertensive activities of Nadolol.]
[L04AA18, everolimus, The metabolism of Nadolol can be decreased when combined with Everolimus.]
[N04AC01, benztropine, Benzatropine may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[R02AX03, benzydamine, Benzydamine may decrease the antihypertensive activities of Nadolol.]
[L01EE01, trametinib, Nadolol may decrease the excretion rate of Trametinib which could result in a higher serum level.]
[P03AX06, benzyl alcohol, The metabolism of Benzyl alcohol can be decreased when combined with Nadolol.]
[V09AX05, florbetapir F-18, Nadolol may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[N06AX28, levomilnacipran, The serum concentration of Nadolol can be increased when it is combined with Levomilnacipran.]
[C08EA02, bepridil, Nadolol may increase the arrhythmogenic activities of Bepridil.]
[C02KX05, riociguat, Nadolol may increase the hypotensive activities of Riociguat.]
[A10BJ03, lixisenatide, The therapeutic efficacy of Lixisenatide can be increased when used in combination with Nadolol.]
[C02KX04, macitentan, Nadolol may increase the hypotensive activities of Macitentan.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Nadolol.]
[N06AX26, vortioxetine, Vortioxetine may decrease the antihypertensive activities of Nadolol.]
[G03AC08, etonogestrel, Etonogestrel may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[J05AP08, sofosbuvir, Nadolol may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[A10BK01, dapagliflozin, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Nadolol.]
[C01CA27, droxidopa, Nadolol may decrease the bronchodilatory activities of Droxidopa.]
[C07AB04, acebutolol, Acebutolol may increase the arrhythmogenic activities of Nadolol.]
[N05CH03, tasimelteon, Nadolol may decrease the excretion rate of Tasimelteon which could result in a higher serum level.]
[L04AA32, apremilast, The metabolism of Nadolol can be increased when combined with Apremilast.]
[L02BG02, formestane, Nadolol may decrease the excretion rate of Formestane which could result in a higher serum level.]
[A16AA06, betaine, Betaine may increase the bradycardic activities of Nadolol.]
[S01ED02, betaxolol, Betaxolol may increase the arrhythmogenic activities of Nadolol.]
[V03AB34, fomepizole, Nadolol may decrease the excretion rate of Fomepizole which could result in a higher serum level.]
[C02CC01, bethanidine, The therapeutic efficacy of Bethanidine can be decreased when used in combination with Nadolol.]
[A10BJ04, albiglutide, The therapeutic efficacy of Albiglutide can be increased when used in combination with Nadolol.]
[L04AC11, siltuximab, The metabolism of Nadolol can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, Nadolol may increase the bradycardic activities of Ceritinib.]
[A03BA03, hyoscyamine, Hyoscyamine may increase the arrhythmogenic activities of Nadolol.]
[A10BK03, empagliflozin, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Nadolol.]
[R03AC19, olodaterol, Nadolol may decrease the bronchodilatory activities of Olodaterol.]
[V08AA01, diatrizoic acid, Diatrizoate may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[S01EE02, unoprostone, Nadolol may increase the hypotensive activities of Unoprostone.]
[V08AA04, iothalamic acid, Diatrizoate may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[A16AX10, eliglustat, The metabolism of Nadolol can be decreased when combined with Eliglustat.]
[J01XA05, oritavancin, The metabolism of Nadolol can be decreased when combined with Oritavancin.]
[S01AA15, dihydrostreptomycin, Dihydrostreptomycin may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[N05AA04, acepromazine, The serum concentration of Nadolol can be increased when it is combined with Acepromazine.]
[V04CX03, methacholine, Nadolol may increase the bronchoconstrictory activities of Methacholine.]
[A10BJ05, dulaglutide, The therapeutic efficacy of Dulaglutide can be increased when used in combination with Nadolol.]
[N04AA02, biperiden, The metabolism of Nadolol can be decreased when combined with Biperiden.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Nadolol.]
[S03AA06, gentamicin, Nadolol may decrease the excretion rate of Gentamicin which could result in a higher serum level.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be decreased when combined with Nadolol.]
[B01AF03, edoxaban, Nadolol may decrease the excretion rate of Edoxaban which could result in a higher serum level.]
[N06AX11, mirtazapine, Mirtazapine may decrease the antihypertensive activities of Nadolol.]
[L04AC10, secukinumab, The metabolism of Nadolol can be increased when combined with Secukinumab.]
[L01XH03, panobinostat, The metabolism of Nadolol can be decreased when combined with Panobinostat.]
[N02BE01, acetaminophen, Acetaminophen may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[L01DC01, bleomycin, Bleomycin may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[C01EB17, ivabradine, Nadolol may increase the bradycardic activities of Ivabradine.]
[J05AF08, adefovir dipivoxil, Adefovir dipivoxil may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[J05AP06, asunaprevir, The metabolism of Nadolol can be decreased when combined with Asunaprevir.]
[N05AX16, brexpiprazole, Nadolol may increase the orthostatic hypotensive activities of Brexpiprazole.]
[A04AD14, rolapitant, The metabolism of Nadolol can be decreased when combined with Rolapitant.]
[G02CX02, flibanserin, Flibanserin may decrease the antihypertensive activities of Nadolol.]
[N05AX15, cariprazine, Cariprazine may decrease the antihypertensive activities of Nadolol.]
[A10BF01, acarbose, The therapeutic efficacy of Acarbose can be increased when used in combination with Nadolol.]
[M02AA25, aceclofenac, Aceclofenac may decrease the antihypertensive activities of Nadolol.]
[M01AB11, acemetacin, Acemetacin may decrease the antihypertensive activities of Nadolol.]
[S01EC01, acetazolamide, Acetazolamide may increase the excretion rate of Nadolol which could result in a lower serum level and potentially a reduction in efficacy.]
[A10AE06, insulin degludec, The therapeutic efficacy of Insulin degludec can be increased when used in combination with Nadolol.]
[N05AB07, acetophenazine, The serum concentration of Nadolol can be increased when it is combined with Acetophenazine.]
[A02BC03, lansoprazole, The metabolism of Nadolol can be decreased when combined with Lansoprazole.]
[V03AB37, idarucizumab, Nadolol may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Nadolol.]
[J02AC05, isavuconazole, The metabolism of Nadolol can be decreased when combined with Isavuconazole.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Nadolol.]
[L01XG03, ixazomib, Nadolol may decrease the excretion rate of Ixazomib which could result in a higher serum level.]
[B01AC27, selexipag, Nadolol may increase the hypotensive activities of Selexipag.]
[A10BB31, acetohexamide, The therapeutic efficacy of Acetohexamide can be increased when used in combination with Nadolol.]
[G04CA01, alfuzosin, Alfuzosin may increase the hypotensive activities of Nadolol.]
[M04AB05, lesinurad, Nadolol may decrease the excretion rate of Lesinurad which could result in a higher serum level.]
[M01AE16, alminoprofen, Alminoprofen may decrease the antihypertensive activities of Nadolol.]
[N03AX23, brivaracetam, Nadolol may decrease the excretion rate of Brivaracetam which could result in a higher serum level.]
[N05BA08, bromazepam, Nadolol may decrease the excretion rate of Bromazepam which could result in a higher serum level.]
[N04BC01, bromocriptine, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Nadolol.]
[A02AD05, aluminum magnesium silicate, Nadolol may decrease the excretion rate of Almasilate which could result in a higher serum level.]
[N06AA19, amineptin, Amineptine may decrease the antihypertensive activities of Nadolol.]
[C08CA01, amlodipine, Amlodipine may increase the arrhythmogenic activities of Nadolol.]
[C03CA02, bumetanide, Bumetanide may increase the excretion rate of Nadolol which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB01, bupivacaine, The serum concentration of Bupivacaine can be increased when it is combined with Nadolol.]
[C07AA19, bupranolol, Nadolol may increase the arrhythmogenic activities of Bupranolol.]
[N07BC01, buprenorphine, The metabolism of Nadolol can be decreased when combined with Buprenorphine.]
[N05BE01, buspirone, Buspirone may decrease the antihypertensive activities of Nadolol.]
[L01XX27, arsenic trioxide, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Nadolol.]
[N06DA03, rivastigmine, Nadolol may increase the bradycardic activities of Rivastigmine.]
[M02AA03, clofezone, Rabeprazole may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[S01GX07, azelastine, The metabolism of Nadolol can be decreased when combined with Azelastine.]
[L01XK03, rucaparib, The metabolism of Nadolol can be decreased when combined with Rucaparib.]
[A07EC04, balsalazide, Balsalazide may decrease the antihypertensive activities of Nadolol.]
[R03CC12, bambuterol, Nadolol may decrease the bronchodilatory activities of Bambuterol.]
[A06AH05, naldemedine, Nadolol may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, Nadolol may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.]
[N02BF02, pregabalin, Pregabalin may increase the bradycardic activities of Nadolol.]
[C09AA07, benazepril, Benazepril may increase the hypotensive activities of Nadolol.]
[A10BX06, benfluorex, The therapeutic efficacy of Benfluorex can be increased when used in combination with Nadolol.]
[A12AA04, calcium carbonate, The therapeutic efficacy of Nadolol can be decreased when used in combination with Calcium carbonate.]
[P01CA02, benznidazole, Nadolol may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[G04BA03, calcium chloride, The therapeutic efficacy of Nadolol can be decreased when used in combination with Calcium chloride.]
[J01XX08, linezolid, Linezolid may increase the hypotensive activities of Nadolol.]
[J05AF06, abacavir, Abacavir may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[J05AE09, tipranavir, The metabolism of Nadolol can be decreased when combined with Tipranavir.]
[D11AX03, calcium gluconate, The therapeutic efficacy of Nadolol can be decreased when used in combination with Calcium gluconate.]
[N07XX13, valbenazine, Nadolol may decrease the excretion rate of Valbenazine which could result in a higher serum level.]
[L04AB02, infliximab, The metabolism of Nadolol can be increased when combined with Infliximab.]
[A12AA01, calcium phosphate, The therapeutic efficacy of Nadolol can be decreased when used in combination with Calcium Phosphate.]
[L01ED04, brigatinib, The excretion of Nadolol can be decreased when combined with Brigatinib.]
[N04BD03, safinamide, Safinamide may increase the hypotensive activities of Nadolol.]
[N07AB02, bethanechol, The risk or severity of adverse effects can be increased when Nadolol is combined with Bethanechol.]
[J01MA23, delafloxacin, Nadolol may decrease the excretion rate of Delafloxacin which could result in a higher serum level.]
[P03AC02, bioallethrin, Nadolol may increase the arrhythmogenic activities of Bioallethrin.]
[S01EB09, acetylcholine, The risk or severity of adverse effects can be increased when Nadolol is combined with Acetylcholine.]
[L01BC06, capecitabine, Capecitabine may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Nadolol.]
[L01EM02, copanlisib, The excretion of Nadolol can be decreased when combined with Copanlisib.]
[L01EF03, abemaciclib, The excretion of Abemaciclib can be decreased when combined with Nadolol.]
[C07AB07, bisoprolol, The risk or severity of adverse effects can be increased when Bisoprolol is combined with Nadolol.]
[R03AC17, bitolterol, Nadolol may decrease the bronchodilatory activities of Bitolterol.]
[J01DC10, cefprozil, Cefprozil may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[C07AA17, bopindolol, Nadolol may increase the bradycardic activities of Bopindolol.]
[C01DX19, nesiritide, The risk or severity of adverse effects can be increased when Nadolol is combined with Nesiritide.]
[C03DA03, canrenone, Canrenone may increase the excretion rate of Nadolol which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA02, budesonide, Nadolol may decrease the excretion rate of Budesonide which could result in a higher serum level.]
[C04AX20, buflomedil, Buflomedil may decrease the antihypertensive activities of Nadolol.]
[M01AB07, bumadizone, Bumadizone may decrease the antihypertensive activities of Nadolol.]
[J05AX18, letermovir, The metabolism of Letermovir can be decreased when combined with Nadolol.]
[N06AA15, butriptyline, Butriptyline may decrease the antihypertensive activities of Nadolol.]
[C01AA02, acetyldigoxins, Nadolol may increase the arrhythmogenic activities of Acetyldigoxin.]
[A10BJ06, semaglutide, The therapeutic efficacy of Semaglutide can be increased when used in combination with Nadolol.]
[N01BX04, capsaicin, Capsaicin may increase the bradycardic activities of Nadolol.]
[A10BK04, ertugliflozin, The therapeutic efficacy of Ertugliflozin can be increased when used in combination with Nadolol.]
[R06AX18, acrivastine, Nadolol may decrease the excretion rate of Acrivastine which could result in a higher serum level.]
[C09AA01, captopril, Captopril may increase the hypotensive activities of Nadolol.]
[S01EB02, carbachol, The risk or severity of adverse effects can be increased when Nadolol is combined with Carbamoylcholine.]
[L02BB05, apalutamide, The excretion of Nadolol can be decreased when combined with Apalutamide.]
[N03AF01, carbamazepine, Nadolol may decrease the excretion rate of Carbamazepine which could result in a higher serum level.]
[A06AC08, calcium polycarbophil, The therapeutic efficacy of Nadolol can be decreased when used in combination with Calcium polycarbophil.]
[C07AG02, carvedilol, Carvedilol may increase the arrhythmogenic activities of Nadolol.]
[B02BX09, fostamatinib, Fostamatinib may increase the antihypertensive activities of Nadolol.]
[N03AX24, cannabidiol, The metabolism of Nadolol can be decreased when combined with Cannabidiol.]
[L04AA37, baricitinib, The excretion of Baricitinib can be decreased when combined with Nadolol.]
[J01DE01, cefepime, Cefepime may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[J01DD10, cefetamet, Cefetamet may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[J01DD09, cefodizime, Cefodizime may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[J01DC11, ceforanide, Ceforanide may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[J01DD13, cefpodoxime, Cefpodoxime may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[L01EC03, encorafenib, The metabolism of Encorafenib can be decreased when combined with Nadolol.]
[J01DD14, ceftibuten, Ceftibuten may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[J01GB14, plazomicin, Nadolol may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[C07AB08, celiprolol, Nadolol may increase the arrhythmogenic activities of Celiprolol.]
[H01CC03, elagolix, The metabolism of Elagolix can be decreased when combined with Nadolol.]
[P01BA07, tafenoquine, The excretion of Nadolol can be decreased when combined with Tafenoquine.]
[A16AX14, migalastat, Nadolol may decrease the excretion rate of Migalastat which could result in a higher serum level.]
[N03AX17, stiripentol, The metabolism of Nadolol can be decreased when combined with Stiripentol.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be decreased when combined with Nadolol.]
[S01GX12, cetirizine, Cetirizine may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[A10BB06, carbutamide, The therapeutic efficacy of Carbutamide can be increased when used in combination with Nadolol.]
[D08AE05, chloroxylenol, Nadolol may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[M01AC05, lornoxicam, Lornoxicam may decrease the antihypertensive activities of Nadolol.]
[N07XX15, inotersen, Inotersen may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[R03BB08, revefenacin, The metabolism of Revefenacin can be decreased when combined with Nadolol.]
[L04AA39, emapalumab, The metabolism of Nadolol can be increased when combined with Emapalumab.]
[L01AD01, carmustine, Carmustine may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[L01EX13, gilteritinib, The excretion of Nadolol can be decreased when combined with Gilteritinib.]
[L01XJ03, glasdegib, The excretion of Nadolol can be decreased when combined with Glasdegib.]
[A06AX05, prucalopride, Nadolol may decrease the excretion rate of Prucalopride which could result in a higher serum level.]
[C01BG07, cifenline, Nadolol may increase the arrhythmogenic activities of Cibenzoline.]
[C09AA08, cilazapril, Nadolol may increase the hypotensive activities of Cilazapril.]
[B01AC23, cilostazol, Cilostazol may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[A03FA08, cinitapride, Cinitapride may decrease the antihypertensive activities of Nadolol.]
[S01ED05, carteolol, Nadolol may increase the arrhythmogenic activities of Carteolol.]
[P02BX04, triclabendazole, The metabolism of Nadolol can be decreased when combined with Triclabendazole.]
[L04AA42, siponimod, Siponimod may decrease the antihypertensive activities of Nadolol.]
[N06BA14, solriamfetol, Solriamfetol may decrease the antihypertensive activities of Nadolol.]
[N05BA09, clobazam, The metabolism of Nadolol can be decreased when combined with Clobazam.]
[V03AE07, calcium acetate, The therapeutic efficacy of Nadolol can be decreased when used in combination with Calcium acetate.]
[C09CA06, candesartan, Nadolol may increase the hypotensive activities of Candesartan.]
[L04AB01, etanercept, The metabolism of Nadolol can be increased when combined with Etanercept.]
[J01DC04, cefaclor, Cefaclor may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[J01DB05, cefadroxil, Cefadroxil may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[J01DC03, cefamandole, Cefamandole may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[J01DB07, cefatrizine, Cefatrizine may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[J01DB04, cefazolin, Cefazolin may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[J01DC09, cefmetazole, Cefmetazole may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[J01DC06, cefonicid, Cefonicid may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[L01EX15, pexidartinib, The excretion of Nadolol can be decreased when combined with Pexidartinib.]
[J01DD12, cefoperazone, Cefoperazone may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[J01DD01, cefotaxime, Cefotaxime may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[J01DC05, cefotetan, Cefotetan may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[N05AA06, cyamemazine, The serum concentration of Nadolol can be increased when it is combined with Cyamemazine.]
[J01DC07, cefotiam, Cefotiam may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[J01DC01, cefoxitin, Cefoxitin may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[J01DD03, cefsulodin, Cefsulodin may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[J01DD02, ceftazidime, Ceftazidime may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[C03BX03, cicletanine, Nadolol may increase the arrhythmogenic activities of Cicletanine.]
[J01DD07, ceftizoxime, Ceftizoxime may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[J01DD04, ceftriaxone, Ceftriaxone may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[S01AA27, cefuroxime, Cefuroxime may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[L01EJ02, fedratinib, The metabolism of Nadolol can be decreased when combined with Fedratinib.]
[N07XX11, pitolisant, The metabolism of Nadolol can be decreased when combined with Pitolisant.]
[N04CX01, istradefylline, The excretion of Nadolol can be decreased when combined with Istradefylline.]
[C03AA09, cyclothiazide, The therapeutic efficacy of Nadolol can be increased when used in combination with Cyclothiazide.]
[G04BE04, yohimbine, Yohimbine may decrease the antihypertensive activities of Nadolol.]
[A10AE03, insulin, regular, pork, The therapeutic efficacy of Insulin pork can be increased when used in combination with Nadolol.]
[J01XX09, daptomycin, Daptomycin may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[J01DB01, cephalexin, Cephalexin may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[J01DB02, cephaloridine, Cefaloridine may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[J01DB03, cephalothin, Cefalotin may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[J01DB08, cephapirin, Cefapirin may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[J01DB09, cephradine, Cefradine may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[N02CC08, lasmiditan, Lasmiditan may increase the bradycardic activities of Nadolol.]
[A16AX16, givosiran, The serum concentration of Nadolol can be increased when it is combined with Givosiran.]
[M09AX08, golodirsen, Nadolol may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[R06AB02, dexchlorpheniramine, The metabolism of Nadolol can be decreased when combined with Dexchlorpheniramine.]
[S01XA12, dexpanthenol, Nadolol may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[L01XX72, tazemetostat, The excretion of Nadolol can be decreased when combined with Tazemetostat.]
[M01AX21, diacetylrhein, The metabolism of Nadolol can be decreased when combined with Diacerein.]
[J05AB16, remdesivir, The excretion of Nadolol can be decreased when combined with Remdesivir.]
[H02CA02, osilodrostat, The metabolism of Nadolol can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Nadolol can be decreased when combined with Amprenavir.]
[N02CC07, frovatriptan, Frovatriptan may decrease the antihypertensive activities of Nadolol.]
[G04CB02, dutasteride, Dutasteride may decrease the antihypertensive activities of Nadolol.]
[R02AA03, dichlorobenzyl alcohol, Nadolol may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, Nadolol may decrease the excretion rate of Dienogest which could result in a higher serum level.]
[N02AA08, dihydrocodeine, The metabolism of Dihydrocodeine can be decreased when combined with Nadolol.]
[N02CC06, eletriptan, Eletriptan may decrease the antihypertensive activities of Nadolol.]
[M01AH02, rofecoxib, Rofecoxib may decrease the antihypertensive activities of Nadolol.]
[C08CA16, clevidipine, Nadolol may increase the arrhythmogenic activities of Clevidipine.]
[C01BD07, dronedarone, Dronedarone may increase the bradycardic activities of Nadolol.]
[C02AA06, methoserpidine, Nadolol may increase the hypotensive activities of Methoserpidine.]
[L01EH03, tucatinib, The excretion of Nadolol can be decreased when combined with Tucatinib.]
[L01EX17, capmatinib, The excretion of Nadolol can be decreased when combined with Capmatinib.]
[N04BX04, opicapone, The risk or severity of adverse effects can be increased when Nadolol is combined with Opicapone.]
[C01CA14, dopexamine, The therapeutic efficacy of Dopexamine can be decreased when used in combination with Nadolol.]
[G04BD09, trospium, The metabolism of Nadolol can be decreased when combined with Trospium.]
[M01AC04, droxicam, Droxicam may decrease the antihypertensive activities of Nadolol.]
[L01EX19, ripretinib, The excretion of Nadolol can be decreased when combined with Ripretinib.]
[V08CA05, mangafodipir, Nadolol may decrease the excretion rate of Mangafodipir which could result in a higher serum level.]
[L01EX22, selpercatinib, Selpercatinib may decrease the antihypertensive activities of Nadolol.]
[M02AA27, dexketoprofen, Dexketoprofen may decrease the antihypertensive activities of Nadolol.]
[C08CA17, levamlodipine, The risk or severity of bradycardia can be increased when Levamlodipine is combined with Nadolol.]
[P01BB01, proguanil, The metabolism of Nadolol can be decreased when combined with Proguanil.]
[M09AX10, risdiplam, The serum concentration of Nadolol can be increased when it is combined with Risdiplam.]
[N02AX07, oliceridine, The metabolism of Oliceridine can be decreased when combined with Nadolol.]
[P01BA01, chloroquine, The metabolism of Nadolol can be decreased when combined with Chloroquine.]
[L01EX23, pralsetinib, The excretion of Nadolol can be decreased when combined with Pralsetinib.]
[C03AA04, chlorothiazide, The therapeutic efficacy of Nadolol can be increased when used in combination with Chlorothiazide.]
[R06AB04, chlorpheniramine, The metabolism of Nadolol can be decreased when combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The metabolism of Nadolol can be decreased when combined with Chlorpromazine.]
[A10BB02, chlorpropamide, The therapeutic efficacy of Chlorpropamide can be increased when used in combination with Nadolol.]
[C03BA04, chlorthalidone, Chlorthalidone may increase the excretion rate of Nadolol which could result in a lower serum level and potentially a reduction in efficacy.]
[M03BB03, chlorzoxazone, Chlorzoxazone may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[A11CC05, cholecalciferol, The metabolism of Nadolol can be decreased when combined with Cholecalciferol.]
[N02BA07, ethenzamide, Ethenzamide may decrease the antihypertensive activities of Nadolol.]
[N02BA03, choline salicylate, Nadolol may decrease the excretion rate of Choline salicylate which could result in a higher serum level.]
[N06BX18, vinpocetine, Nadolol may increase the arrhythmogenic activities of Vinpocetine.]
[M01AB08, etodolac, Etodolac may decrease the antihypertensive activities of Nadolol.]
[M02AA06, etofenamate, Etofenamate may decrease the antihypertensive activities of Nadolol.]
[B06AC06, berotralstat, The metabolism of Nadolol can be decreased when combined with Berotralstat.]
[M09AA01, hydroquinine, Nadolol may increase the arrhythmogenic activities of Hydroquinine.]
[M01AX25, chondroitin sulfates, Nadolol may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[L01FX21, naxitamab, Naxitamab may decrease the antihypertensive activities of Nadolol.]
[C01DX22, vericiguat, The risk or severity of adverse effects can be increased when Nadolol is combined with Vericiguat.]
[V03AF12, trilaciclib, The excretion of Nadolol can be decreased when combined with Trilaciclib.]
[M01AE05, fenbufen, Fenbufen may decrease the antihypertensive activities of Nadolol.]
[C01CA19, fenoldopam, Fenoldopam may increase the hypotensive activities of Nadolol.]
[N06BA08, fenozolone, Fenozolone may decrease the antihypertensive activities of Nadolol.]
[G04CB01, finasteride, Finasteride may decrease the antihypertensive activities of Nadolol.]
[J01DD15, cefdinir, Cefdinir may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[S02BA08, fluocinolone acetonide, Fluocinolone acetonide may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[N02BG07, flupirtine, Nadolol may decrease the excretion rate of Flupirtine which could result in a higher serum level.]
[R03CC15, formoterol, Nadolol may decrease the bronchodilatory activities of Formoterol.]
[A10AF01, insulin, regular, human, The therapeutic efficacy of Insulin human can be increased when used in combination with Nadolol.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Nadolol.]
[N01AB05, trichloroethylene, Trichloroethylene may decrease the antihypertensive activities of Nadolol.]
[L03AB10, peginterferon alfa-2b, The metabolism of Nadolol can be decreased when combined with Peginterferon alfa-2b.]
[H04AA02, dasiglucagon, The therapeutic efficacy of Nadolol can be decreased when used in combination with Dasiglucagon.]
[A02BA01, cimetidine, The metabolism of Nadolol can be decreased when combined with Cimetidine.]
[V08CA04, gadoteridol, Gadoteridol may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[N07CA02, cinnarizine, Cinnarizine may increase the arrhythmogenic activities of Nadolol.]
[S03AA07, ciprofloxacin, The excretion of Nadolol can be decreased when combined with Ciprofloxacin.]
[L01XA01, cisplatin, Nadolol may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N06AB04, citalopram, The metabolism of Nadolol can be decreased when combined with Citalopram.]
[C03DA05, finerenone, Finerenone may increase the excretion rate of Nadolol which could result in a lower serum level and potentially a reduction in efficacy.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Nadolol is combined with Fexinidazole.]
[V09AB03, ioflupane I-123, Nadolol may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.]
[V09AA01, technetium Tc 99m exametazime, Nadolol may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Nadolol may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[R06AA04, clemastine, The metabolism of Nadolol can be decreased when combined with Clemastine.]
[M01AG01, mefenamic acid, Mefenamic acid may decrease the antihypertensive activities of Nadolol.]
[A10BB12, glimepiride, The therapeutic efficacy of Glimepiride can be increased when used in combination with Nadolol.]
[A10BB08, gliquidone, The therapeutic efficacy of Gliquidone can be increased when used in combination with Nadolol.]
[R03CC13, clenbuterol, Nadolol may decrease the bronchodilatory activities of Clenbuterol.]
[A12AA02, calcium glubionate, The therapeutic efficacy of Nadolol can be decreased when used in combination with Calcium glubionate anhydrous.]
[N06AX25, St. John's wort extract, The metabolism of Nadolol can be decreased when combined with St. John's Wort.]
[L03AB15, ropeginterferon alfa-2b, The metabolism of Nadolol can be decreased when combined with Ropeginterferon alfa-2b.]
[N01BB10, levobupivacaine, The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Nadolol.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be decreased when combined with Nadolol.]
[N03AE01, clonazepam, Clonazepam may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[S01EA04, clonidine, The risk or severity of hypotension can be increased when Clonidine is combined with Nadolol.]
[J05AH02, oseltamivir, Oseltamivir may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[A10BX16, tirzepatide, The therapeutic efficacy of Tirzepatide can be increased when used in combination with Nadolol.]
[C03BA03, clopamide, Clopamide may increase the excretion rate of Nadolol which could result in a lower serum level and potentially a reduction in efficacy.]
[A04AA01, ondansetron, The metabolism of Nadolol can be decreased when combined with Ondansetron.]
[N05AH02, clozapine, The metabolism of Nadolol can be decreased when combined with Clozapine.]
[A10BX01, guar gum, The therapeutic efficacy of Guar gum can be increased when used in combination with Nadolol.]
[A10BK06, sotagliflozin, The therapeutic efficacy of Sotagliflozin can be increased when used in combination with Nadolol.]
[J01GB12, arbekacin, Nadolol may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[S02DA02, cocaine, The metabolism of Nadolol can be decreased when combined with Cocaine.]
[C02KB01, metyrosine, Metyrosine may increase the hypotensive activities of Nadolol.]
[L04AC21, bimekizumab, The metabolism of Nadolol can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, Proquazone may decrease the antihypertensive activities of Nadolol.]
[R05DA04, codeine, The metabolism of Nadolol can be decreased when combined with Codeine.]
[M03AC05, hexafluorenium, Hexafluronium may increase the bradycardic activities of Nadolol.]
[M04AC01, colchicine, Nadolol may decrease the excretion rate of Colchicine which could result in a higher serum level.]
[J01XB01, colistin, Nadolol may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, Cefpirome may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[C01BA13, hydroquinidine, Nadolol may increase the arrhythmogenic activities of Hydroquinidine.]
[N01AB07, desflurane, Desflurane may decrease the antihypertensive activities of Nadolol.]
[A04AA03, tropisetron, Nadolol may increase the arrhythmogenic activities of Tropisetron.]
[C04AX28, ifenprodil, Ifenprodil may decrease the antihypertensive activities of Nadolol.]
[A10BX03, nateglinide, The therapeutic efficacy of Nateglinide can be increased when used in combination with Nadolol.]
[N02BA16, imidazole-2-hydroxybenzoate, Imidazole salicylate may decrease the antihypertensive activities of Nadolol.]
[H01AC03, mecasermin, The therapeutic efficacy of Mecasermin can be increased when used in combination with Nadolol.]
[A10AE04, insulin glargine, The therapeutic efficacy of Insulin glargine can be increased when used in combination with Nadolol.]
[R03BA08, ciclesonide, The metabolism of Ciclesonide can be decreased when combined with Nadolol.]
[B01AC10, indobufen, Indobufen may decrease the antihypertensive activities of Nadolol.]
[J05AB14, valganciclovir, Nadolol may decrease the excretion rate of Valganciclovir which could result in a higher serum level.]
[J05AF09, emtricitabine, The excretion of Nadolol can be decreased when combined with Emtricitabine.]
[C05BB03, invert sugar, Nadolol may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Nadolol may decrease the excretion rate of Iodixanol which could result in a higher serum level.]
[V08AB05, iopromide, Nadolol may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Nadolol may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Nadolol may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, Valdecoxib may decrease the antihypertensive activities of Nadolol.]
[H01AX01, pegvisomant, Pegvisomant may increase the bradycardic activities of Nadolol.]
[C01AA06, lanatoside C, Nadolol may increase the bradycardic activities of Lanatoside C.]
[A03AX10, isometheptene, The therapeutic efficacy of Isometheptene can be decreased when used in combination with Nadolol.]
[N02CC05, almotriptan, Almotriptan may decrease the antihypertensive activities of Nadolol.]
[M01AH04, parecoxib, Parecoxib may decrease the antihypertensive activities of Nadolol.]
[J02AC02, itraconazole, The risk or severity of hyperkalemia can be increased when Itraconazole is combined with Nadolol.]
[B01AB12, bemiparin, The risk or severity of hyperkalemia can be increased when Nadolol is combined with Bemiparin.]
[S01AD03, acyclovir, The excretion of Nadolol can be decreased when combined with Acyclovir.]
[N05BA10, ketazolam, Nadolol may decrease the excretion rate of Ketazolam which could result in a higher serum level.]
[M01AA06, kebuzone, Kebuzone may decrease the antihypertensive activities of Nadolol.]
[L01EA01, imatinib, The serum concentration of Nadolol can be increased when it is combined with Imatinib.]
[S01EE04, travoprost, Travoprost may increase the hypotensive activities of Nadolol.]
[S01EE03, bimatoprost, Bimatoprost may increase the hypotensive activities of Nadolol.]
[C08CA09, lacidipine, Nadolol may increase the hypotensive activities of Lacidipine.]
[N03AX09, lamotrigine, Lamotrigine may increase the arrhythmogenic activities of Nadolol.]
[N07BC04, lofexidine, The therapeutic efficacy of Lofexidine can be decreased when used in combination with Nadolol.]
[M01AB09, lonazolac, Lonazolac may decrease the antihypertensive activities of Nadolol.]
[M02AA31, loxoprofen, Loxoprofen may decrease the antihypertensive activities of Nadolol.]
[J01DC08, loracarbef, Loracarbef may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[C09AA03, lisinopril, Lisinopril may increase the hypotensive activities of Nadolol.]
[A06AD01, magnesium carbonate, Nadolol may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.]
[C08CA11, manidipine, Nadolol may increase the arrhythmogenic activities of Manidipine.]
[A08AA09, mefenorex, Mefenorex may decrease the antihypertensive activities of Nadolol.]
[C07AA14, mepindolol, Nadolol may increase the bradycardic activities of Mepindolol.]
[R06AD07, mequitazine, The metabolism of Nadolol can be decreased when combined with Mequitazine.]
[J01DH02, meropenem, Meropenem may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[C01EB10, adenosine, Adenosine may increase the arrhythmogenic activities of Nadolol.]
[C04AX01, cyclandelate, Nadolol may increase the arrhythmogenic activities of Cyclandelate.]
[R03CB02, methoxyphenamine, The therapeutic efficacy of Nadolol can be decreased when used in combination with Methoxyphenamine.]
[C03DA04, eplerenone, Eplerenone may increase the excretion rate of Nadolol which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AD03, metylperon, Nadolol may increase the arrhythmogenic activities of Melperone.]
[C03AA07, cyclopenthiazide, The therapeutic efficacy of Nadolol can be increased when used in combination with Cyclopenthiazide.]
[A10BF02, miglitol, The therapeutic efficacy of Miglitol can be increased when used in combination with Nadolol.]
[J05AF07, tenofovir disoproxil, Tenofovir disoproxil may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[N06AX07, minaprine, Minaprine may increase the bradycardic activities of Nadolol.]
[S01XA18, cyclosporine, The metabolism of Nadolol can be decreased when combined with Cyclosporine.]
[N06AG02, moclobemide, Moclobemide may increase the hypotensive activities of Nadolol.]
[C09AA13, moexipril, Moexipril may increase the hypotensive activities of Nadolol.]
[M02AA02, mofebutazone, Mofebutazone may decrease the antihypertensive activities of Nadolol.]
[M01AX22, morniflumate, Morniflumate may decrease the antihypertensive activities of Nadolol.]
[C03XA02, conivaptan, Conivaptan may increase the excretion rate of Nadolol which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AC05, moxonidine, The therapeutic efficacy of Moxonidine can be decreased when used in combination with Nadolol.]
[G04BE09, vardenafil, Vardenafil may increase the antihypertensive activities of Nadolol.]
[M01AH05, etoricoxib, Etoricoxib may decrease the antihypertensive activities of Nadolol.]
[L01AX04, dacarbazine, Dacarbazine may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[M03CA01, dantrolene, The risk or severity of hyperkalemia can be increased when Nadolol is combined with Dantrolene.]
[C02CC04, debrisoquin, Nadolol may increase the hypotensive activities of Debrisoquine.]
[A04AD11, nabilone, The risk or severity of adverse effects can be increased when Nabilone is combined with Nadolol.]
[M01AX01, nabumetone, Nabumetone may decrease the antihypertensive activities of Nadolol.]
[N07BB05, nalmefene, Nadolol may decrease the excretion rate of Nalmefene which could result in a higher serum level.]
[B05XA15, potassium lactate, Potassium lactate may increase the hyperkalemic activities of Nadolol.]
[C07AB12, nebivolol, Nadolol may increase the arrhythmogenic activities of Nebivolol.]
[S01GX04, nedocromil, Nedocromil may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[N06AX06, nefazodone, The serum concentration of Nadolol can be increased when it is combined with Nefazodone.]
[C01DX16, nicorandil, Nicorandil may increase the hypotensive activities of Nadolol.]
[L02BB02, nilutamide, Nilutamide may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[C01CA23, theodrenaline, The therapeutic efficacy of Nadolol can be decreased when used in combination with Theodrenaline.]
[C01CA05, norfenefrine, The therapeutic efficacy of Norfenefrine can be decreased when used in combination with Nadolol.]
[B01AX05, fondaparinux, Fondaparinux may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[N06AB10, escitalopram, The serum concentration of Nadolol can be increased when it is combined with Escitalopram.]
[G04BD08, solifenacin, Solifenacin may decrease the antihypertensive activities of Nadolol.]
[A07EC03, olsalazine, Olsalazine may decrease the antihypertensive activities of Nadolol.]
[N06AA01, desipramine, The metabolism of Nadolol can be decreased when combined with Desipramine.]
[C01AA07, deslanoside, Deslanoside may increase the arrhythmogenic activities of Nadolol.]
[H01BA02, desmopressin, Desmopressin may decrease the antihypertensive activities of Nadolol.]
[V04CH02, indigo carmine, Nadolol may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[J01DH03, ertapenem, Ertapenem may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[C09XA02, aliskiren, Nadolol may increase the hypotensive activities of Aliskiren.]
[M01AE12, oxaprozin, Oxaprozin may decrease the antihypertensive activities of Nadolol.]
[G04BD04, oxybutynin, The metabolism of Nadolol can be decreased when combined with Oxybutynin.]
[A08AA04, dexfenfluramine, The metabolism of Nadolol can be decreased when combined with Dexfenfluramine.]
[L04AB04, adalimumab, The metabolism of Nadolol can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The metabolism of Nadolol can be decreased when combined with Gefitinib.]
[N06BA02, dextroamphetamine, The therapeutic efficacy of Nadolol can be decreased when used in combination with Amphetamine.]
[R05DA09, dextromethorphan, The metabolism of Nadolol can be decreased when combined with Dextromethorphan.]
[N06AB05, paroxetine, The metabolism of Nadolol can be decreased when combined with Paroxetine.]
[P03AC04, permethrin, Nadolol may decrease the excretion rate of Permethrin which could result in a higher serum level.]
[N05BA01, diazepam, Diazepam may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[V03AH01, diazoxide, Diazoxide may increase the hypotensive activities of Nadolol.]
[N06AA08, dibenzepin, Dibenzepin may decrease the antihypertensive activities of Nadolol.]
[S02DA04, dibucaine, Cinchocaine may increase the bradycardic activities of Nadolol.]
[R05DA08, pholcodine, Nadolol may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[S01EC02, dichlorphenamide, Diclofenamide may increase the excretion rate of Nadolol which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC03, diclofenac, Diclofenac may decrease the antihypertensive activities of Nadolol.]
[J05AD01, foscarnet, Foscarnet may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[A03AA07, dicyclomine, Dicyclomine may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[J05AF02, didanosine, Didanosine may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[C02DG01, pinacidil, Nadolol may increase the hypotensive activities of Pinacidil.]
[A03AX04, pinaverium, Nadolol may increase the arrhythmogenic activities of Pinaverium.]
[A10BG03, pioglitazone, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Nadolol.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Nadolol is combined with Pipamperone.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Nadolol.]
[R03CC07, pirbuterol, Nadolol may decrease the bronchodilatory activities of Pirbuterol.]
[C03CA03, piretanide, Piretanide may increase the excretion rate of Nadolol which could result in a lower serum level and potentially a reduction in efficacy.]
[P02CB02, diethylcarbamazine, Diethylcarbamazine may increase the bradycardic activities of Nadolol.]
[A08AA03, diethylpropion, The therapeutic efficacy of Nadolol can be decreased when used in combination with Diethylpropion.]
[C08CA03, isradipine, Isradipine may increase the arrhythmogenic activities of Nadolol.]
[D07XC04, diflucortolone, Nadolol may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[N02BA11, diflunisal, Diflunisal may decrease the antihypertensive activities of Nadolol.]
[C01AA04, digitoxin, Nadolol may increase the arrhythmogenic activities of Digitoxin.]
[C01AA05, digoxin, Digoxin may increase the arrhythmogenic activities of Nadolol.]
[C02DB01, dihydralazine, Nadolol may increase the hypotensive activities of Dihydralazine.]
[C04AE04, dihydroergocristine, Nadolol may increase the vasoconstricting activities of Dihydroergocristine.]
[N02CA01, dihydroergotamine, Nadolol may increase the vasoconstricting activities of Dihydroergotamine.]
[N02AA03, hydromorphone, Hydromorphone may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[L04AX04, lenalidomide, Lenalidomide may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[J05AE08, atazanavir, Atazanavir may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[B01AC21, treprostinil, Treprostinil may increase the hypotensive activities of Nadolol.]
[H03BC01, potassium perchlorate, Potassium perchlorate may increase the hyperkalemic activities of Nadolol.]
[V03AB04, pralidoxime, Pralidoxime may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[C08DB01, diltiazem, Diltiazem may increase the arrhythmogenic activities of Nadolol.]
[V03AB09, dimercaprol, Nadolol may decrease the excretion rate of Dimercaprol which could result in a higher serum level.]
[R03CC08, procaterol, Nadolol may decrease the bronchodilatory activities of Procaterol.]
[M02AX03, dimethyl sulfoxide, The metabolism of Nadolol can be decreased when combined with Dimethyl sulfoxide.]
[N02BB04, propyphenazone, Propyphenazone may decrease the antihypertensive activities of Nadolol.]
[M01AB14, proglumetacin, Proglumetacin may decrease the antihypertensive activities of Nadolol.]
[R06AA02, diphenhydramine, The metabolism of Nadolol can be decreased when combined with Diphenhydramine.]
[C09AA06, quinapril, Quinapril may increase the hypotensive activities of Nadolol.]
[B01AC07, dipyridamole, Dipyridamole may increase the bradycardic activities of Nadolol.]
[N06BA11, dexmethylphenidate, Dexmethylphenidate may decrease the antihypertensive activities of Nadolol.]
[N06AA23, quinupramine, Quinupramine may decrease the antihypertensive activities of Nadolol.]
[A03FA02, cisapride, The metabolism of Nadolol can be decreased when combined with Cisapride.]
[C09AA05, ramipril, Ramipril may increase the hypotensive activities of Nadolol.]
[N05AL04, remoxipride, The metabolism of Nadolol can be decreased when combined with Remoxipride.]
[R03CC14, reproterol, The therapeutic efficacy of Reproterol can be decreased when used in combination with Nadolol.]
[S01AX06, resorcinol, Nadolol may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, Disopyramide may increase the bradycardic activities of Nadolol.]
[N07AA03, distigmine, Distigmine may increase the bradycardic activities of Nadolol.]
[S02AA12, rifamycin SV, The metabolism of Nadolol can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Nadolol can be increased when combined with Rifapentine.]
[D06AX11, rifaximin, The metabolism of Nadolol can be increased when combined with Rifaximin.]
[N05AX08, risperidone, Nadolol may increase the hypotensive activities of Risperidone.]
[R06AE09, levocetirizine, Nadolol may decrease the excretion rate of Levocetirizine which could result in a higher serum level.]
[N01BB09, ropivacaine, The risk or severity of adverse effects can be increased when Ropivacaine is combined with Nadolol.]
[L01EX01, sunitinib, The therapeutic efficacy of Sunitinib can be increased when used in combination with Nadolol.]
[C03XA01, tolvaptan, Tolvaptan may increase the excretion rate of Nadolol which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XG01, bortezomib, The metabolism of Nadolol can be decreased when combined with Bortezomib.]
[G04BE08, tadalafil, Tadalafil may increase the hypotensive activities of Nadolol.]
[S01BC05, ketorolac, Ketorolac may decrease the antihypertensive activities of Nadolol.]
[C02KX02, ambrisentan, Nadolol may increase the hypotensive activities of Ambrisentan.]
[C01EB18, ranolazine, The serum concentration of Nadolol can be increased when it is combined with Ranolazine.]
[N02BA06, salsalate, Salsalate may decrease the antihypertensive activities of Nadolol.]
[R03AC12, salmeterol, Nadolol may decrease the bronchodilatory activities of Salmeterol.]
[H05BA01, salmon calcitonin, Salmon calcitonin may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[C01CA07, dobutamine, Nadolol may decrease the bronchodilatory activities of Dobutamine.]
[A03FA03, domperidone, The metabolism of Nadolol can be decreased when combined with Domperidone.]
[C01CA04, dopamine, Dopamine may decrease the antihypertensive activities of Nadolol.]
[N06AA16, dothiepin, The metabolism of Nadolol can be decreased when combined with Dosulepin.]
[R07AB01, doxapram, Doxapram may decrease the antihypertensive activities of Nadolol.]
[N06AA12, doxepin, Nadolol may increase the orthostatic hypotensive activities of Doxepin.]
[L01DB01, doxorubicin, The metabolism of Nadolol can be decreased when combined with Doxorubicin.]
[J01AA02, doxycycline, Doxycycline may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[N06AB06, sertraline, The serum concentration of Nadolol can be increased when it is combined with Sertraline.]
[N01AB08, sevoflurane, Sevoflurane may decrease the antihypertensive activities of Nadolol.]
[N05AD08, droperidol, Nadolol may increase the orthostatic hypotensive activities of Droperidol.]
[A08AA10, sibutramine, The serum concentration of Nadolol can be increased when it is combined with Sibutramine.]
[C10AA01, simvastatin, The metabolism of Nadolol can be decreased when combined with Simvastatin.]
[V03AG05, sodium phosphate, Sodium phosphate, monobasic may increase the hyperkalemic activities of Nadolol.]
[A12CA02, sodium sulfate, Nadolol may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.]
[C09AA11, spirapril, Nadolol may increase the hypotensive activities of Spirapril.]
[R03DA01, dyphylline, Dyphylline may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[N02CC01, sumatriptan, Sumatriptan may decrease the antihypertensive activities of Nadolol.]
[V04CX07, edrophonium, Edrophonium may increase the bradycardic activities of Nadolol.]
[C07AB13, talinolol, Nadolol may increase the arrhythmogenic activities of Talinolol.]
[L01AX03, temozolomide, Temozolomide may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[M01AC02, tenoxicam, Tenoxicam may decrease the antihypertensive activities of Nadolol.]
[G04CA03, terazosin, Nadolol may increase the orthostatic hypotensive activities of Terazosin.]
[D01BA02, terbinafine, The metabolism of Nadolol can be decreased when combined with Terbinafine.]
[G04BD05, terodiline, Nadolol may increase the arrhythmogenic activities of Terodiline.]
[C07AA16, tertatolol, Nadolol may increase the arrhythmogenic activities of Tertatolol.]
[S01GA02, tetrahydrozoline, The therapeutic efficacy of Tetryzoline can be decreased when used in combination with Nadolol.]
[N06AX14, tianeptine, Tianeptine may decrease the antihypertensive activities of Nadolol.]
[C09AA02, enalapril, Enalapril may increase the hypotensive activities of Nadolol.]
[M01AG02, tolfenamic acid, Tolfenamic acid may decrease the antihypertensive activities of Nadolol.]
[N06AG03, toloxatone, Toloxatone may increase the hypotensive activities of Nadolol.]
[N06BA09, atomoxetine, Atomoxetine may decrease the antihypertensive activities of Nadolol.]
[N03AX11, topiramate, Topiramate may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[C03CA04, torsemide, Torasemide may increase the excretion rate of Nadolol which could result in a lower serum level and potentially a reduction in efficacy.]
[R01AA09, tramazoline, Tramazoline may decrease the antihypertensive activities of Nadolol.]
[C09AA10, trandolapril, Trandolapril may increase the hypotensive activities of Nadolol.]
[N05CC01, chloral hydrate, Nadolol may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.]
[R03CC11, tulobuterol, The therapeutic efficacy of Tulobuterol can be decreased when used in combination with Nadolol.]
[N01AB04, enflurane, Enflurane may increase the cardiodepressant activities of Nadolol.]
[C02CA06, urapidil, Nadolol may increase the orthostatic hypotensive activities of Urapidil.]
[L01CA04, vinorelbine, The metabolism of Nadolol can be decreased when combined with Vinorelbine.]
[S01FB02, ephedrine, The therapeutic efficacy of Ephedrine can be decreased when used in combination with Nadolol.]
[S01GX10, epinastine, The metabolism of Nadolol can be decreased when combined with Epinastine.]
[N06AX16, venlafaxine, The metabolism of Nadolol can be decreased when combined with Venlafaxine.]
[C01CX07, xamoterol, The therapeutic efficacy of Xamoterol can be decreased when used in combination with Nadolol.]
[S01GA03, xylometazoline, Nadolol may increase the arrhythmogenic activities of Xylometazoline.]
[C08CA12, mepirodipine, Nadolol may increase the antihypertensive activities of Barnidipine.]
[S01EA01, epinephrine, Nadolol may decrease the bronchodilatory activities of Epinephrine.]
[C09AA15, zofenopril, Nadolol may increase the hypotensive activities of Zofenopril.]
[N05CF02, zolpidem, The metabolism of Nadolol can be decreased when combined with Zolpidem.]
[M01AB04, zomepirac, Zomepirac may decrease the antihypertensive activities of Nadolol.]
[N03AX15, zonisamide, Zonisamide may increase the arrhythmogenic activities of Nadolol.]
[A10AB06, insulin glulisine, human, The therapeutic efficacy of Insulin glulisine can be increased when used in combination with Nadolol.]
[L01XA02, carboplatin, Carboplatin may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[C02AC02, guanfacine, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Nadolol.]
[B01AC11, iloprost, Iloprost may increase the hypotensive activities of Nadolol.]
[C01BG01, moricizine, Moricizine may increase the arrhythmogenic activities of Nadolol.]
[G02AB03, ergonovine, The therapeutic efficacy of Ergometrine can be decreased when used in combination with Nadolol.]
[C04AE01, ergoloid mesylates, USP, Nadolol may increase the vasoconstricting activities of Ergoloid mesylate.]
[N02CA02, ergotamine, Nadolol may increase the vasoconstricting activities of Ergotamine.]
[L03AX05, pidotimod, Nadolol may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[N05CD04, estazolam, Nadolol may decrease the excretion rate of Estazolam which could result in a higher serum level.]
[A02BC02, pantoprazole, Pantoprazole may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[H05BX01, cinacalcet, The metabolism of Nadolol can be decreased when combined with Cinacalcet.]
[G03CA03, estradiol, Estradiol may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[G03CA57, estrogens, conjugated (USP), Conjugated estrogens may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[J04AK02, ethambutol, Ethambutol may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[C10AA04, fluvastatin, The metabolism of Nadolol can be decreased when combined with Fluvastatin.]
[V08CA03, gadodiamide, Gadodiamide may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[C01CA15, gepefrine, The therapeutic efficacy of Nadolol can be decreased when used in combination with Gepefrine.]
[V03AF05, amifostine, Nadolol may increase the hypotensive activities of Amifostine.]
[C01BD05, ibutilide, Ibutilide may increase the arrhythmogenic activities of Nadolol.]
[N04AA05, profenamine, Profenamine may increase the bradycardic activities of Nadolol.]
[N03AD01, ethosuximide, Ethosuximide may increase the arrhythmogenic activities of Nadolol.]
[M01AC06, meloxicam, Meloxicam may decrease the antihypertensive activities of Nadolol.]
[S01XA06, ethylmorphine, The metabolism of Ethylmorphine can be decreased when combined with Nadolol.]
[C01CA01, etilefrine, The therapeutic efficacy of Etilefrine can be decreased when used in combination with Nadolol.]
[N01AX07, etomidate, The therapeutic efficacy of Etomidate can be decreased when used in combination with Nadolol.]
[N05AE03, sertindole, The metabolism of Sertindole can be decreased when combined with Nadolol.]
[C01BA05, ajmaline, Nadolol may increase the arrhythmogenic activities of Ajmaline.]
[L04AD02, tacrolimus, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Nadolol.]
[A02BA04, nizatidine, Nizatidine may increase the bradycardic activities of Nadolol.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Nadolol.]
[R06AX12, terfenadine, The metabolism of Nadolol can be decreased when combined with Terfenadine.]
[P01AX07, trimetrexate, Trimetrexate may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[N06AX12, bupropion, The metabolism of Nadolol can be decreased when combined with Bupropion.]
[N06AB08, fluvoxamine, The metabolism of Nadolol can be decreased when combined with Fluvoxamine.]
[C01BB03, tocainide, Tocainide may increase the arrhythmogenic activities of Nadolol.]
[C01BC08, encainide, Nadolol may increase the arrhythmogenic activities of Encainide.]
[L02AE02, leuprolide, Leuprolide may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[M01CB01, gold sodium thiomalate, Nadolol may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[B05AA05, dextran, Nadolol may decrease the excretion rate of Dextran which could result in a higher serum level.]
[V03AF02, dexrazoxane, Dexrazoxane may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[A02BA03, famotidine, The excretion of Nadolol can be decreased when combined with Famotidine.]
[A16AA01, levocarnitine, Levocarnitine may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[C08CA02, felodipine, Felodipine may increase the arrhythmogenic activities of Nadolol.]
[C08EA01, fendiline, Nadolol may increase the arrhythmogenic activities of Fendiline.]
[N03AX26, fenfluramine, The metabolism of Nadolol can be decreased when combined with Fenfluramine.]
[M01AE04, fenoprofen, Fenoprofen may decrease the antihypertensive activities of Nadolol.]
[R03CC04, fenoterol, Nadolol may decrease the bronchodilatory activities of Fenoterol.]
[N02AB03, fentanyl, Fentanyl may decrease the antihypertensive activities of Nadolol.]
[R03CC02, albuterol, Nadolol may decrease the bronchodilatory activities of Salbutamol.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Clofarabine is combined with Nadolol.]
[N07AX03, cevimeline, The risk or severity of adverse effects can be increased when Nadolol is combined with Cevimeline.]
[G04BD02, flavoxate, Flavoxate may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[C01BC04, flecainide, Flecainide may increase the arrhythmogenic activities of Nadolol.]
[N02BG04, floctafenine, The risk or severity of adverse effects can be increased when Nadolol is combined with Floctafenine.]
[J02AC01, fluconazole, The risk or severity of hyperkalemia can be increased when Fluconazole is combined with Nadolol.]
[J02AX01, flucytosine, Flucytosine may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[V03AB25, flumazenil, Nadolol may decrease the excretion rate of Flumazenil which could result in a higher serum level.]
[N07CA03, flunarizine, Nadolol may increase the arrhythmogenic activities of Flunarizine.]
[N06AA14, melitracen, Melitracen may decrease the antihypertensive activities of Nadolol.]
[V03AZ01, ethanol, Ethanol may increase the hypotensive activities of Nadolol.]
[L01BC09, floxuridine, Floxuridine may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[N06AB03, fluoxetine, The serum concentration of Nadolol can be increased when it is combined with Fluoxetine.]
[N05AF01, flupenthixol, Nadolol may increase the orthostatic hypotensive activities of Flupentixol.]
[N05AB02, fluphenazine, The serum concentration of Nadolol can be increased when it is combined with Fluphenazine.]
[N05CD01, flurazepam, Flurazepam may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[S01BC04, flurbiprofen, Flurbiprofen may decrease the antihypertensive activities of Nadolol.]
[N05AG01, fluspirilene, Nadolol may increase the arrhythmogenic activities of Fluspirilene.]
[L02BB01, flutamide, Flutamide may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[V04CX02, folic acid, Folic acid may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[S02AA17, fosfomycin, Fosfomycin may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[S01AA07, framycetin, Framycetin may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[L01BC03, tegafur, Nadolol may decrease the excretion rate of Tegafur which could result in a higher serum level.]
[N06BX17, adrafinil, The therapeutic efficacy of Adrafinil can be decreased when used in combination with Nadolol.]
[G01AX06, furazolidone, Furazolidone may increase the hypotensive activities of Nadolol.]
[J05AE10, darunavir, The metabolism of Nadolol can be decreased when combined with Darunavir.]
[C03CA01, furosemide, Furosemide may increase the excretion rate of Nadolol which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CF04, eszopiclone, Eszopiclone may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[N06DA04, galantamine, Galantamine may increase the bradycardic activities of Nadolol.]
[C08DA02, gallopamil, Nadolol may increase the arrhythmogenic activities of Gallopamil.]
[S01AD09, ganciclovir, The excretion of Nadolol can be decreased when combined with Ganciclovir.]
[N03AA04, barbexaclone, Barbexaclone may increase the hypotensive activities of Nadolol.]
[C10AB04, gemfibrozil, Nadolol may decrease the excretion rate of Gemfibrozil which could result in a higher serum level.]
[J01XA03, telavancin, Nadolol may decrease the excretion rate of Telavancin which could result in a higher serum level.]
[N04BC06, cabergoline, Nadolol may increase the vasoconstricting activities of Cabergoline.]
[A10BJ02, liraglutide, The therapeutic efficacy of Liraglutide can be increased when used in combination with Nadolol.]
[A12AA13, calcium citrate, The therapeutic efficacy of Nadolol can be decreased when used in combination with Calcium citrate.]
[A12AA10, calcium gluceptate, The therapeutic efficacy of Nadolol can be decreased when used in combination with Calcium glucoheptonate.]
[A12AA05, calcium lactate, The therapeutic efficacy of Nadolol can be decreased when used in combination with Calcium lactate.]
[A12AA30, calcium levulinate, The therapeutic efficacy of Nadolol can be decreased when used in combination with Calcium levulinate.]
[N03AD03, methsuximide, Nadolol may increase the arrhythmogenic activities of Methsuximide.]
[N01AH02, alfentanil, Alfentanil may decrease the antihypertensive activities of Nadolol.]
[A10BB01, glyburide, The therapeutic efficacy of Glyburide can be increased when used in combination with Nadolol.]
[A10BB09, gliclazide, The therapeutic efficacy of Gliclazide can be increased when used in combination with Nadolol.]
[A10BB07, glipizide, The therapeutic efficacy of Glipizide can be increased when used in combination with Nadolol.]
[H04AA01, glucagon, The therapeutic efficacy of Nadolol can be decreased when used in combination with Glucagon.]
[N05CM18, dexmedetomidine, The therapeutic efficacy of Dexmedetomidine can be decreased when used in combination with Nadolol.]
[C05AE01, nitroglycerin, Nitroglycerin may increase the hypotensive activities of Nadolol.]
[C01BD04, dofetilide, Dofetilide may increase the arrhythmogenic activities of Nadolol.]
[C02CA04, doxazosin, Nadolol may increase the orthostatic hypotensive activities of Doxazosin.]
[H01AB01, thyrotropin alfa, The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Nadolol.]
[L01EX02, sorafenib, Sorafenib may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[C07AB09, esmolol, Esmolol may increase the arrhythmogenic activities of Nadolol.]
[M01CB04, aurothioglucose, Nadolol may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Nadolol may decrease the excretion rate of Pegaptanib which could result in a higher serum level.]
[C09AA09, fosinopril, Fosinopril may increase the hypotensive activities of Nadolol.]
[S01EX01, guanethidine, Guanethidine may increase the hypotensive activities of Nadolol.]
[L02AE03, goserelin, Goserelin may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[P01BX01, halofantrine, The metabolism of Nadolol can be decreased when combined with Halofantrine.]
[N05AD01, haloperidol, The serum concentration of Nadolol can be increased when it is combined with Haloperidol.]
[N01AB01, halothane, Halothane may decrease the antihypertensive activities of Nadolol.]
[N05AH04, quetiapine, Quetiapine may increase the hypotensive activities of Nadolol.]
[N06BX13, idebenone, Nadolol may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[A10AD05, insulin aspart, human, The therapeutic efficacy of Insulin aspart can be increased when used in combination with Nadolol.]
[M04AA01, allopurinol, Allopurinol may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[C09CA01, losartan, Losartan may increase the arrhythmogenic activities of Nadolol.]
[S01XA14, heparin, The risk or severity of hyperkalemia can be increased when Heparin is combined with Nadolol.]
[G03DC01, allylestrenol, Nadolol may decrease the excretion rate of Allylestrenol which could result in a higher serum level.]
[A07EC02, mesalamine, Mesalazine may decrease the antihypertensive activities of Nadolol.]
[C01CE02, milrinone, Milrinone may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[N05CA16, hexobarbital, Hexobarbital may increase the hypotensive activities of Nadolol.]
[R03CC05, hexoprenaline, Nadolol may decrease the bronchodilatory activities of Hexoprenaline.]
[J05AG01, nevirapine, The metabolism of Nadolol can be decreased when combined with Nevirapine.]
[C08CA10, nilvadipine, Nadolol may increase the arrhythmogenic activities of Nilvadipine.]
[M02AA26, nimesulide, Nimesulide may decrease the antihypertensive activities of Nadolol.]
[C09AA04, perindopril, Perindopril may increase the hypotensive activities of Nadolol.]
[C02DB02, hydralazine, Nadolol may increase the hypotensive activities of Hydralazine.]
[C03AA03, hydrochlorothiazide, The therapeutic efficacy of Nadolol can be increased when used in combination with Hydrochlorothiazide.]
[C03AA02, hydroflumethiazide, The therapeutic efficacy of Nadolol can be increased when used in combination with Hydroflumethiazide.]
[B05XA17, potassium acetate, Potassium acetate may increase the hyperkalemic activities of Nadolol.]
[S01XA07, aluminum potassium sulfate, Potassium alum may increase the hyperkalemic activities of Nadolol.]
[A12BA02, potassium citrate, Potassium citrate may increase the excretion rate of Nadolol which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Hydroxocobalamin may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[G04BD06, propiverine, Nadolol may increase the orthostatic hypotensive activities of Propiverine.]
[P01BA02, hydroxychloroquine, The risk or severity of QTc prolongation can be decreased when Hydroxychloroquine is combined with Nadolol.]
[B05AA07, hetastarch, Nadolol may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[N05BB01, hydroxyzine, The metabolism of Nadolol can be decreased when combined with Hydroxyzine.]
[C02AC06, rilmenidine, The therapeutic efficacy of Rilmenidine can be decreased when used in combination with Nadolol.]
[R02AX02, ibuprofen, Ibuprofen may decrease the antihypertensive activities of Nadolol.]
[B05XA08, sodium acetate, Nadolol may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[L01DB06, idarubicin, The metabolism of Nadolol can be decreased when combined with Idarubicin.]
[L01AA06, ifosfamide, Ifosfamide may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[N01AH03, sufentanil, Sufentanil may decrease the antihypertensive activities of Nadolol.]
[N06AA02, imipramine, The metabolism of Nadolol can be decreased when combined with Imipramine.]
[L01CD01, paclitaxel, The risk or severity of adverse effects can be increased when Nadolol is combined with Paclitaxel.]
[R01AD07, tixocortol, Nadolol may decrease the excretion rate of Tixocortol which could result in a higher serum level.]
[M03BX02, tizanidine, The therapeutic efficacy of Tizanidine can be decreased when used in combination with Nadolol.]
[L01CE01, topotecan, The excretion of Topotecan can be decreased when combined with Nadolol.]
[C03BA11, indapamide, The therapeutic efficacy of Indapamide can be increased when used in combination with Nadolol.]
[S01BC01, indomethacin, Indomethacin may decrease the antihypertensive activities of Nadolol.]
[C02CA02, indoramin, Nadolol may increase the orthostatic hypotensive activities of Indoramin.]
[A11HA07, inositol, Nadolol may decrease the excretion rate of Inositol which could result in a higher serum level.]
[N06AX17, milnacipran, The serum concentration of Nadolol can be increased when it is combined with Milnacipran.]
[S01XA28, varenicline, The risk or severity of adverse effects can be increased when Nadolol is combined with Varenicline.]
[A10BH01, sitagliptin, The therapeutic efficacy of Sitagliptin can be increased when used in combination with Nadolol.]
[N05BA12, alprazolam, Alprazolam may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[N05CH02, ramelteon, Ramelteon may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[A10BH02, vildagliptin, The therapeutic efficacy of Vildagliptin can be increased when used in combination with Nadolol.]
[C10AA06, cerivastatin, The metabolism of Nadolol can be decreased when combined with Cerivastatin.]
[C07AA01, alprenolol, Alprenolol may increase the arrhythmogenic activities of Nadolol.]
[C03BA02, quinethazone, Quinethazone may increase the excretion rate of Nadolol which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB01, ipecac, Nadolol may decrease the excretion rate of Ipecac which could result in a higher serum level.]
[N06AA13, iprindole, Iprindole may decrease the antihypertensive activities of Nadolol.]
[N06AF05, iproniazid, Iproniazid may increase the hypotensive activities of Nadolol.]
[N05AA07, chlorproethazine, The serum concentration of Nadolol can be increased when it is combined with Chlorproethazine.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the hypotensive activities of Nadolol.]
[S01EC03, dorzolamide, Dorzolamide may increase the hypotensive activities of Nadolol.]
[R03CC06, isoetharine, Nadolol may decrease the bronchodilatory activities of Isoetharine.]
[C09AA16, imidapril, Nadolol may increase the hypotensive activities of Imidapril.]
[N01AB06, isoflurane, Isoflurane may decrease the antihypertensive activities of Nadolol.]
[S01EB07, isoflurophate, Isoflurophate may increase the bradycardic activities of Nadolol.]
[N04BX02, entacapone, The metabolism of Nadolol can be decreased when combined with Entacapone.]
[J04AC01, isoniazid, Isoniazid may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[J05AX05, inosine pranobex, Nadolol may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[R03CB01, isoproterenol, Nadolol may decrease the bronchodilatory activities of Isoprenaline.]
[A10BJ01, exenatide, The therapeutic efficacy of Exenatide can be increased when used in combination with Nadolol.]
[C01DA14, isosorbide mononitrate, The risk or severity of adverse effects can be increased when Isosorbide mononitrate is combined with Nadolol.]
[C05AE02, isosorbide dinitrate, The risk or severity of adverse effects can be increased when Isosorbide dinitrate is combined with Nadolol.]
[D10BA01, isotretinoin, Isotretinoin may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[C04AA01, isoxsuprine, The therapeutic efficacy of Isoxsuprine can be decreased when used in combination with Nadolol.]
[N06AX18, reboxetine, The metabolism of Nadolol can be decreased when combined with Reboxetine.]
[S01AA24, kanamycin, Nadolol may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[L04AC07, tocilizumab, The metabolism of Nadolol can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, Ketamine may increase the bradycardic activities of Nadolol.]
[C02KD01, ketanserin, Nadolol may increase the hypotensive activities of Ketanserin.]
[B01AC22, prasugrel, Nadolol may decrease the excretion rate of Prasugrel which could result in a higher serum level.]
[J02AB02, ketoconazole, The metabolism of Nadolol can be decreased when combined with Ketoconazole.]
[H02CA04, levoketoconazole, The excretion of Nadolol can be decreased when combined with Levoketoconazole.]
[N05AH03, olanzapine, Nadolol may increase the orthostatic hypotensive activities of Olanzapine.]
[M02AA10, ketoprofen, Ketoprofen may decrease the antihypertensive activities of Nadolol.]
[L04AA24, abatacept, The metabolism of Nadolol can be increased when combined with Abatacept.]
[C01CA22, arbutamine, Nadolol may decrease the bronchodilatory activities of Arbutamine.]
[N04BC09, rotigotine, The metabolism of Nadolol can be decreased when combined with Rotigotine.]
[D10AX03, azelaic acid, Azelaic acid may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[M01AE11, tiaprofenic acid, Tiaprofenic acid may decrease the antihypertensive activities of Nadolol.]
[C07AG01, labetalol, Nadolol may increase the orthostatic hypotensive activities of Labetalol.]
[N04BB01, amantadine, Amantadine may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[C02AA05, deserpidine, Deserpidine may increase the hypotensive activities of Nadolol.]
[N07AA30, ambenonium, Ambenonium may increase the bradycardic activities of Nadolol.]
[A06AX03, lubiprostone, Lubiprostone may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[N03AX18, lacosamide, Nadolol may increase the bradycardic activities of Lacosamide.]
[C03CC01, ethacrynic acid, Etacrynic acid may increase the excretion rate of Nadolol which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BA01, levodopa, The risk or severity of hypotension and orthostatic hypotension can be increased when Nadolol is combined with Levodopa.]
[S02DA01, lidocaine, The serum concentration of Lidocaine can be increased when it is combined with Nadolol.]
[C08EX01, lidoflazine, Nadolol may increase the arrhythmogenic activities of Lidoflazine.]
[S01AA21, amikacin, Nadolol may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[C03DB01, amiloride, Amiloride may increase the excretion rate of Nadolol which could result in a lower serum level and potentially a reduction in efficacy.]
[N02CA07, lisuride, Nadolol may increase the vasoconstricting activities of Lisuride.]
[N06AA07, lofepramine, Lofepramine may decrease the antihypertensive activities of Nadolol.]
[A07DA03, loperamide, Loperamide may increase the arrhythmogenic activities of Nadolol.]
[A12AA11, calcium pangamate, The therapeutic efficacy of Nadolol can be decreased when used in combination with Calcium pangamate.]
[N05BA06, lorazepam, Lorazepam may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[C10AA02, lovastatin, The metabolism of Nadolol can be decreased when combined with Lovastatin.]
[L01EG01, temsirolimus, The metabolism of Nadolol can be decreased when combined with Temsirolimus.]
[B05XA11, magnesium chloride, Nadolol may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, Nadolol may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.]
[V04CC02, magnesium sulfate, Magnesium sulfate may increase the arrhythmogenic activities of Nadolol.]
[L01BA05, pralatrexate, Nadolol may decrease the excretion rate of Pralatrexate which could result in a higher serum level.]
[V04CX04, mannitol, Mannitol may increase the excretion rate of Nadolol which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA21, maprotiline, Maprotiline may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[C02BB01, mecamylamine, Mecamylamine may increase the hypotensive activities of Nadolol.]
[L01AA05, mechlorethamine, Mechlorethamine may increase the bradycardic activities of Nadolol.]
[R06AE05, meclizine, The metabolism of Nadolol can be decreased when combined with Meclizine.]
[M02AA18, meclofenamic acid, Meclofenamic acid may decrease the antihypertensive activities of Nadolol.]
[C01AA08, medigoxin, Nadolol may increase the arrhythmogenic activities of Metildigoxin.]
[P01BC02, mefloquine, The risk or severity of QTc prolongation can be decreased when Mefloquine is combined with Nadolol.]
[C03BA05, mefruside, Mefruside may increase the excretion rate of Nadolol which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AB06, nadroparin, The risk or severity of hyperkalemia can be increased when Nadolol is combined with Nadroparin.]
[B01AB05, enoxaparin, The risk or severity of hyperkalemia can be increased when Nadolol is combined with Enoxaparin.]
[B01AB04, dalteparin, The risk or severity of hyperkalemia can be increased when Nadolol is combined with Dalteparin.]
[N06DX01, memantine, Memantine may increase the bradycardic activities of Nadolol.]
[N02AB02, meperidine, Meperidine may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[C01CA11, mephentermine, The therapeutic efficacy of Nadolol can be decreased when used in combination with Mephentermine.]
[N03AB04, mephenytoin, The metabolism of Nadolol can be decreased when combined with Mephenytoin.]
[N03AA01, mephobarbital, Methylphenobarbital may increase the hypotensive activities of Nadolol.]
[N01BB03, mepivacaine, The serum concentration of Mepivacaine can be increased when it is combined with Nadolol.]
[G04BX16, tiopronin, Nadolol may decrease the excretion rate of Tiopronin which could result in a higher serum level.]
[C03BC01, mersalyl, Mersalyl may increase the excretion rate of Nadolol which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AC03, mesoridazine, The serum concentration of Nadolol can be increased when it is combined with Mesoridazine.]
[N05AX13, paliperidone, Nadolol may increase the orthostatic hypotensive activities of Paliperidone.]
[C01CA09, metaraminol, The therapeutic efficacy of Metaraminol can be decreased when used in combination with Nadolol.]
[A10BA02, metformin, The therapeutic efficacy of Metformin can be increased when used in combination with Nadolol.]
[A04AA04, dolasetron, The metabolism of Nadolol can be decreased when combined with Dolasetron.]
[H01CB03, lanreotide, Nadolol may increase the bradycardic activities of Lanreotide.]
[N07BC02, methadone, The metabolism of Nadolol can be decreased when combined with Methadone.]
[N06BA03, methamphetamine, The therapeutic efficacy of Nadolol can be decreased when used in combination with Metamfetamine.]
[J05AF05, lamivudine, Lamivudine may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[S01EC05, methazolamide, Methazolamide may increase the excretion rate of Nadolol which could result in a lower serum level and potentially a reduction in efficacy.]
[G02CB05, metergoline, Nadolol may increase the vasoconstricting activities of Metergoline.]
[H03BB02, methimazole, The excretion of Nadolol can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, Nadolol may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[N05CA15, methohexital, Methohexital may increase the hypotensive activities of Nadolol.]
[A11HA02, pyridoxine, Pyridoxine may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[N02BG08, ziconotide, Nadolol may increase the arrhythmogenic activities of Ziconotide.]
[L04AX03, methotrexate, Methotrexate may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[N05AA02, methotrimeprazine, The metabolism of Nadolol can be decreased when combined with Methotrimeprazine.]
[C01CA10, methoxamine, The therapeutic efficacy of Methoxamine can be decreased when used in combination with Nadolol.]
[D05BA02, methoxsalen, Methoxsalen may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[N02BG09, methoxyflurane, Methoxyflurane may decrease the antihypertensive activities of Nadolol.]
[C03AA08, methyclothiazide, The therapeutic efficacy of Nadolol can be increased when used in combination with Methyclothiazide.]
[C02AB01, methyldopa, The therapeutic efficacy of Methyldopa can be decreased when used in combination with Nadolol.]
[V04CG05, methylene blue, The serum concentration of Nadolol can be increased when it is combined with Methylene blue.]
[G02AB01, methylergonovine, Nadolol may increase the vasoconstricting activities of Methylergometrine.]
[N06BA04, methylphenidate, Methylphenidate may decrease the antihypertensive activities of Nadolol.]
[G03EK01, methyltestosterone, Nadolol may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.]
[N02CA04, methysergide, Nadolol may increase the vasoconstricting activities of Methysergide.]
[A03FA01, metoclopramide, Metoclopramide may increase the bradycardic activities of Nadolol.]
[C03BA08, metolazone, Metolazone may increase the excretion rate of Nadolol which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB02, metoprolol, Metoprolol may increase the arrhythmogenic activities of Nadolol.]
[V04CD01, metyrapone, Metyrapone may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[C01BB02, mexiletine, Mexiletine may increase the arrhythmogenic activities of Nadolol.]
[N06AX03, mianserin, Mianserin may decrease the antihypertensive activities of Nadolol.]
[S02AA13, miconazole, The metabolism of Nadolol can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, Aminophenazone may decrease the antihypertensive activities of Nadolol.]
[B01AB07, parnaparin, The risk or severity of hyperkalemia can be increased when Nadolol is combined with Parnaparin.]
[N05CD08, midazolam, Midazolam may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[C01CA17, midodrine, The therapeutic efficacy of Midodrine can be decreased when used in combination with Nadolol.]
[G03XB01, mifepristone, The therapeutic efficacy of Mifepristone can be increased when used in combination with Nadolol.]
[B01AB10, tinzaparin, The risk or severity of hyperkalemia can be increased when Nadolol is combined with Tinzaparin.]
[J05AH01, zanamivir, Zanamivir may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[C09CA03, valsartan, Valsartan may increase the hypotensive activities of Nadolol.]
[D11AX01, minoxidil, Minoxidil may increase the hypotensive activities of Nadolol.]
[N06BA12, lisdexamfetamine, The therapeutic efficacy of Nadolol can be decreased when used in combination with Lisdexamfetamine.]
[L03AC01, aldesleukin, The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nadolol.]
[C01DX12, molsidomine, Molsidomine may increase the hypotensive activities of Nadolol.]
[C01BD01, amiodarone, The therapeutic efficacy of Nadolol can be increased when used in combination with Amiodarone.]
[N06AA09, amitriptyline, The metabolism of Amitriptyline can be decreased when combined with Nadolol.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Morphine is combined with Nadolol.]
[A04AA05, palonosetron, Palonosetron may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[J01DD06, moxalactam, Latamoxef may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[L04AB05, certolizumab pegol, The metabolism of Nadolol can be increased when combined with Certolizumab pegol.]
[G04BA01, ammonium chloride, The risk or severity of hyperkalemia can be increased when Nadolol is combined with Ammonium chloride.]
[L01EX03, pazopanib, The metabolism of Nadolol can be decreased when combined with Pazopanib.]
[L04AA06, mycophenolic acid, Mycophenolic acid may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[N05CA02, amobarbital, Amobarbital may increase the hypotensive activities of Nadolol.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be decreased when Amodiaquine is combined with Nadolol.]
[G04CA04, silodosin, The risk or severity of orthostatic hypotension and dizziness can be increased when Nadolol is combined with Silodosin.]
[N06AA17, amoxapine, The metabolism of Amoxapine can be decreased when combined with Nadolol.]
[C01DA05, pentaerythritol tetranitrate, Nadolol may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.]
[J01CA04, amoxicillin, Amoxicillin may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[N04BC04, ropinirole, The risk or severity of adverse effects can be increased when Ropinirole is combined with Nadolol.]
[V03AB15, naloxone, Naloxone may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[L04AC03, anakinra, The metabolism of Nadolol can be increased when combined with Anakinra.]
[S01GA01, naphazoline, The therapeutic efficacy of Naphazoline can be decreased when used in combination with Nadolol.]
[N06BA01, amphetamine, The therapeutic efficacy of Nadolol can be decreased when used in combination with Amphetamine.]
[M02AA12, naproxen, Naproxen may decrease the antihypertensive activities of Nadolol.]
[A10BG01, troglitazone, The therapeutic efficacy of Troglitazone can be increased when used in combination with Nadolol.]
[N06AX21, duloxetine, The risk or severity of orthostatic hypotension and syncope can be increased when Nadolol is combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Tolcapone is combined with Nadolol.]
[S03AA01, neomycin, Nadolol may decrease the excretion rate of Neomycin which could result in a higher serum level.]
[N01AH06, remifentanil, Remifentanil may decrease the antihypertensive activities of Nadolol.]
[A10BX02, repaglinide, The therapeutic efficacy of Repaglinide can be increased when used in combination with Nadolol.]
[C01CX08, levosimendan, Levosimendan may increase the arrhythmogenic activities of Nadolol.]
[B01AC17, tirofiban, Tirofiban may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[S01EB06, neostigmine, Neostigmine may increase the bradycardic activities of Nadolol.]
[N05AX14, iloperidone, Nadolol may increase the orthostatic hypotensive activities of Iloperidone.]
[J02AA01, amphotericin B, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Nadolol.]
[S01AA19, ampicillin, Ampicillin may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[L03AX16, plerixafor, Nadolol may decrease the excretion rate of Plerixafor which could result in a higher serum level.]
[S01AA23, netilmicin, Nadolol may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, The serum concentration of Nadolol can be increased when it is combined with Desvenlafaxine.]
[C09CA07, telmisartan, Telmisartan may increase the hypotensive activities of Nadolol.]
[J05AB11, valacyclovir, Valaciclovir may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[C01CE01, inamrinone, Nadolol may decrease the excretion rate of Amrinone which could result in a higher serum level.]
[C10AD02, niacin, The metabolism of Nadolol can be decreased when combined with Niacin.]
[N06AF02, nialamide, Nialamide may increase the hypotensive activities of Nadolol.]
[C08CA04, nicardipine, Nicardipine may increase the arrhythmogenic activities of Nadolol.]
[C04AE02, nicergoline, Nadolol may increase the vasoconstricting activities of Nicergoline.]
[N07BA01, nicotine, The risk or severity of adverse effects can be increased when Nadolol is combined with Nicotine.]
[C08CA05, nifedipine, The risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Nadolol.]
[M02AA17, niflumic acid, Niflumic acid may decrease the antihypertensive activities of Nadolol.]
[V03AB22, amyl nitrite, The risk or severity of adverse effects can be increased when Nadolol is combined with Amyl Nitrite.]
[C08CA06, nimodipine, Nimodipine may increase the arrhythmogenic activities of Nadolol.]
[C08CA07, nisoldipine, Nisoldipine may increase the arrhythmogenic activities of Nadolol.]
[C08CA08, nitrendipine, Nitrendipine may increase the arrhythmogenic activities of Nadolol.]
[R07AX01, nitric oxide, The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Nadolol.]
[J01XE01, nitrofurantoin, The risk or severity of hyperkalemia can be increased when Nitrofurantoin is combined with Nadolol.]
[N05CF03, zaleplon, Zaleplon may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[N04BC05, pramipexole, The risk or severity of adverse effects can be increased when Pramipexole is combined with Nadolol.]
[C02DD01, nitroprusside, Nitroprusside may increase the hypotensive activities of Nadolol.]
[N01AX13, nitrous oxide, Nitrous oxide may decrease the antihypertensive activities of Nadolol.]
[C01CA03, norepinephrine, Nadolol may decrease the bronchodilatory activities of Norepinephrine.]
[C02KX01, bosentan, Bosentan may increase the hypotensive activities of Nadolol.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be decreased when combined with Nadolol.]
[G02CA02, nylidrin, Nadolol may increase the arrhythmogenic activities of Nylidrin.]
[B01AB08, reviparin, The risk or severity of hyperkalemia can be increased when Nadolol is combined with Reviparin.]
[H01CB02, octreotide, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Nadolol.]
[L04AC04, rilonacept, The metabolism of Nadolol can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Nadolol can be decreased when combined with Omeprazole.]
[N06AA05, opipramol, Opipramol may decrease the antihypertensive activities of Nadolol.]
[N02AA02, opium, Nadolol may decrease the excretion rate of Opium which could result in a higher serum level.]
[R03CB03, metaproterenol, Nadolol may decrease the bronchodilatory activities of Orciprenaline.]
[G04CA02, tamsulosin, Nadolol may increase the orthostatic hypotensive activities of Tamsulosin.]
[C01AC01, ouabain, Nadolol may increase the bradycardic activities of Ouabain.]
[J01CF04, oxacillin, Oxacillin may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[P02BA02, oxamniquine, The metabolism of Nadolol can be decreased when combined with Oxamniquine.]
[N05BA04, oxazepam, Oxazepam may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[C07AA02, oxprenolol, Nadolol may increase the arrhythmogenic activities of Oxprenolol.]
[N02AA05, oxycodone, The metabolism of Nadolol can be decreased when combined with Oxycodone.]
[C01DX03, oxyfedrine, The therapeutic efficacy of Oxyfedrine can be decreased when used in combination with Nadolol.]
[S01GA04, oxymetazoline, The risk or severity of cardiovascular complications can be increased when Nadolol is combined with Oxymetazoline.]
[N02AA11, oxymorphone, The metabolism of Nadolol can be decreased when combined with Oxymorphone.]
[S01BC02, oxyphenbutazone, Oxyphenbutazone may decrease the antihypertensive activities of Nadolol.]
[N05AH05, asenapine, Nadolol may increase the orthostatic hypotensive activities of Asenapine.]
[B01AB09, danaparoid, The risk or severity of hyperkalemia can be increased when Nadolol is combined with Danaparoid.]
[M03AC01, pancuronium, Pancuronium may increase the bradycardic activities of Nadolol.]
[J04AB30, capreomycin, Nadolol may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[G04BE02, papaverine, The risk or severity of adverse effects can be increased when Papaverine is combined with Nadolol.]
[C02KC01, pargyline, Pargyline may increase the hypotensive activities of Nadolol.]
[A07AA06, paromomycin, Paromomycin may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[G04BD11, fesoterodine, Nadolol may decrease the excretion rate of Fesoterodine which could result in a higher serum level.]
[C07AA23, penbutolol, Nadolol may increase the hypotensive activities of Penbutolol.]
[N05AG03, penfluridol, Nadolol may increase the arrhythmogenic activities of Penfluridol.]
[J01CE09, penicillin G procaine, Nadolol may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.]
[N05CA01, pentobarbital, Pentobarbital may increase the hypotensive activities of Nadolol.]
[L01XX08, pentostatin, Nadolol may decrease the excretion rate of Pentostatin which could result in a higher serum level.]
[C04AD03, pentoxifylline, Pentoxifylline may increase the hypotensive activities of Nadolol.]
[N05AB10, perazine, The serum concentration of Nadolol can be increased when it is combined with Perazine.]
[N04BC02, pergolide, The therapeutic efficacy of Pergolide can be decreased when used in combination with Nadolol.]
[C08EX02, perhexiline, Perhexiline may increase the arrhythmogenic activities of Nadolol.]
[N05AB03, perphenazine, The serum concentration of Nadolol can be increased when it is combined with Perphenazine.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Nadolol.]
[G04BX06, phenazopyridine, Phenazopyridine may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[N06AF03, phenelzine, Phenelzine may increase the hypotensive activities of Nadolol.]
[A10BA01, phenformin, The therapeutic efficacy of Phenformin can be increased when used in combination with Nadolol.]
[N03AA02, phenobarbital, Phenobarbital may increase the hypotensive activities of Nadolol.]
[C04AX02, phenoxybenzamine, Nadolol may increase the orthostatic hypotensive activities of Phenoxybenzamine.]
[A08AA01, phentermine, The therapeutic efficacy of Nadolol can be decreased when used in combination with Phentermine.]
[V03AB36, phentolamine, Nadolol may increase the orthostatic hypotensive activities of Phentolamine.]
[M02AA01, phenylbutazone, Phenylbutazone may decrease the antihypertensive activities of Nadolol.]
[S01GA05, phenylephrine, The therapeutic efficacy of Phenylephrine can be decreased when used in combination with Nadolol.]
[R01BA01, phenylpropanolamine, Nadolol may decrease the bronchodilatory activities of Phenylpropanolamine.]
[N03AB02, phenytoin, The metabolism of Nadolol can be decreased when combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Nadolol can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, Levofloxacin may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[V03AB19, physostigmine, Physostigmine may increase the bradycardic activities of Nadolol.]
[B02BA01, vitamin K1, Phylloquinone may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[J05AB12, cidofovir, Cidofovir may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[C08CX01, mibefradil, Nadolol may increase the arrhythmogenic activities of Mibefradil.]
[S01EB01, pilocarpine, The risk or severity of adverse effects can be increased when Nadolol is combined with Pilocarpine.]
[N05AG02, pimozide, The metabolism of Pimozide can be decreased when combined with Nadolol.]
[C07AA03, pindolol, Pindolol may increase the hypotensive activities of Nadolol.]
[J01CA12, piperacillin, Piperacillin may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[J05AE01, saquinavir, The metabolism of Nadolol can be decreased when combined with Saquinavir.]
[P02CB01, piperazine, The metabolism of Nadolol can be decreased when combined with Piperazine.]
[N05AC04, pipothiazine, The serum concentration of Nadolol can be increased when it is combined with Pipotiazine.]
[N06BX03, piracetam, Nadolol may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[C09CA02, eprosartan, Eprosartan may increase the hypotensive activities of Nadolol.]
[S01BC06, piroxicam, Piroxicam may decrease the antihypertensive activities of Nadolol.]
[J01DD16, cefditoren, Cefditoren may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[N02CX01, pizotyline, Nadolol may increase the orthostatic hypotensive activities of Pizotifen.]
[J05AG02, delavirdine, The metabolism of Nadolol can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, Irbesartan may increase the hypotensive activities of Nadolol.]
[A10BG02, rosiglitazone, The therapeutic efficacy of Rosiglitazone can be increased when used in combination with Nadolol.]
[L04AC08, canakinumab, The metabolism of Nadolol can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, The therapeutic efficacy of Nadolol can be increased when used in combination with Polythiazide.]
[J05AE03, ritonavir, The metabolism of Nadolol can be decreased when combined with Ritonavir.]
[A10BH03, saxagliptin, The therapeutic efficacy of Saxagliptin can be increased when used in combination with Nadolol.]
[B05XA01, potassium chloride, Potassium chloride may increase the hyperkalemic activities of Nadolol.]
[V03AB21, potassium iodide, Potassium Iodide may increase the hyperkalemic activities of Nadolol.]
[A10AD04, insulin lispro, The therapeutic efficacy of Insulin lispro can be increased when used in combination with Nadolol.]
[C07AB01, practolol, Nadolol may increase the arrhythmogenic activities of Practolol.]
[C01BA08, prajmaline, Nadolol may increase the arrhythmogenic activities of Prajmaline.]
[C02CA01, prazosin, The risk or severity of hypotension can be increased when Prazosin is combined with Nadolol.]
[H02AB07, prednisone, Prednisone may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[C01DX02, prenylamine, Nadolol may increase the arrhythmogenic activities of Prenylamine.]
[P01BA03, primaquine, The metabolism of Nadolol can be decreased when combined with Primaquine.]
[N03AA03, primidone, Primidone may increase the hypotensive activities of Nadolol.]
[M04AB01, probenecid, Probenecid may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[C01BA02, procainamide, Procainamide may increase the arrhythmogenic activities of Nadolol.]
[S01HA05, procaine, Procaine may increase the bradycardic activities of Nadolol.]
[L01XB01, procarbazine, Procarbazine may increase the hypotensive activities of Nadolol.]
[C10AB05, fenofibrate, Fenofibrate may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[N05AB04, prochlorperazine, The serum concentration of Nadolol can be increased when it is combined with Prochlorperazine.]
[G03DA04, progesterone, The metabolism of Nadolol can be decreased when combined with Progesterone.]
[N05AA03, promazine, The serum concentration of Nadolol can be increased when it is combined with Promazine.]
[R06AD02, promethazine, The serum concentration of Nadolol can be increased when it is combined with Promethazine.]
[C01BC03, propafenone, The risk or severity of adverse effects can be increased when Propafenone is combined with Nadolol.]
[A03AB05, propantheline, Propantheline may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[N05AC01, periciazine, The serum concentration of Nadolol can be increased when it is combined with Periciazine.]
[N05CM06, propiomazine, Nadolol may increase the orthostatic hypotensive activities of Propiomazine.]
[N01AX10, propofol, Propofol may decrease the antihypertensive activities of Nadolol.]
[N02AC04, propoxyphene, The metabolism of Nadolol can be decreased when combined with Dextropropoxyphene.]
[C07AA05, propranolol, Propranolol may increase the arrhythmogenic activities of Nadolol.]
[C01AB01, proscillaridin, Nadolol may increase the bradycardic activities of Proscillaridin.]
[N02CC04, rizatriptan, Rizatriptan may decrease the antihypertensive activities of Nadolol.]
[B01AC09, epoprostenol, Epoprostenol may increase the hypotensive activities of Nadolol.]
[N06AA11, protriptyline, Protriptyline may decrease the antihypertensive activities of Nadolol.]
[R01BA02, pseudoephedrine, The therapeutic efficacy of Nadolol can be decreased when used in combination with Pseudoephedrine.]
[N05AX12, aripiprazole, The risk or severity of hypotension can be increased when Aripiprazole is combined with Nadolol.]
[N07XX07, dalfampridine, Nadolol may decrease the excretion rate of Dalfampridine which could result in a higher serum level.]
[P02CC01, pyrantel, Nadolol may decrease the excretion rate of Pyrantel which could result in a higher serum level.]
[J04AK01, pyrazinamide, Pyrazinamide may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[A12BA05, potassium gluconate, Potassium gluconate may increase the hyperkalemic activities of Nadolol.]
[N07AA02, pyridostigmine, Pyridostigmine may increase the bradycardic activities of Nadolol.]
[R06AC01, pyrilamine, The metabolism of Nadolol can be decreased when combined with Mepyramine.]
[P01BD01, pyrimethamine, The excretion of Nadolol can be decreased when combined with Pyrimethamine.]
[C01BA01, quinidine, Quinidine may increase the arrhythmogenic activities of Nadolol.]
[P01BC01, quinine, The metabolism of Nadolol can be decreased when combined with Quinine.]
[A02BA02, ranitidine, The metabolism of Nadolol can be decreased when combined with Ranitidine.]
[C02AA01, rescinnamine, Rescinnamine may decrease the antihypertensive activities of Nadolol.]
[C02AA02, reserpine, The therapeutic efficacy of Nadolol can be increased when used in combination with Reserpine.]
[J05AP01, ribavirin, Ribavirin may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[J04AB02, rifampin, The metabolism of Nadolol can be increased when combined with Rifampicin.]
[R03AC05, rimiterol, The therapeutic efficacy of Rimiterol can be decreased when used in combination with Nadolol.]
[G02CA01, ritodrine, Nadolol may decrease the bronchodilatory activities of Ritodrine.]
[N02BA05, salicylamide, Salicylamide may decrease the antihypertensive activities of Nadolol.]
[A07EC01, sulfasalazine, Sulfasalazine may decrease the antihypertensive activities of Nadolol.]
[S01BC08, salicylic acid, Salicylic acid may decrease the antihypertensive activities of Nadolol.]
[N05CA06, secobarbital, Secobarbital may increase the hypotensive activities of Nadolol.]
[N04BD01, selegiline, Selegiline may increase the hypotensive activities of Nadolol.]
[L01FA03, obinutuzumab, Nadolol may increase the hypotensive activities of Obinutuzumab.]
[J01GB08, sisomicin, Nadolol may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Nadolol may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[V04CC01, sorbitol, Nadolol may decrease the excretion rate of Sorbitol which could result in a higher serum level.]
[C07AA07, sotalol, Sotalol may increase the arrhythmogenic activities of Nadolol.]
[C03DA01, spironolactone, Spironolactone may increase the excretion rate of Nadolol which could result in a lower serum level and potentially a reduction in efficacy.]
